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ABSTRACT 
 
Background: Up to 70% of stroke patients experience cognitive impairment in at 
least one cognitive domain. Guidelines currently recommend that stroke 
patients be screened as soon as is reasonably practicable for potential cognitive 
impairment. For a screening test to be diagnostically valid it needs to 
demonstrate adequate levels of sensitivity and specificity. Cognitive impairment 
can be identified globally or as an impairment in a specific cognitive domain. 
Research into commonly used screening tests for cognitive impairment has 
failed to identify a test with adequate levels of sensitivity and specificity for 
cognitive impairment in an acute stroke population. The Repeatable Battery for 
the Assessment of Neuropsychological Status (RBANS) has demonstrated 
adequate diagnostic validity in differing diagnostic groups and has shown to be 
appropriate for use with acute stroke patients. However, the RBANS has not yet 
been evaluated for sensitivity and specificity for cognitive impairment following 
stroke. 
 
Aims: The aim of this pilot study was to establish whether an extended study of 
the diagnostic validity of the RBANS as a sensitive and specific screening test 
of post stroke cognitive impairment was justified. The study objectives were to 
compare the RBANS scores with full neuropsychological test battery overall 
conclusions for cognitive impairment and non-impairment, to compare the 
RBANS with measures of impairment in specific cognitive domains, and to 
identify RBANS optimum cut-off scores for discrimination of cognitive 
impairment / non-impairment in an acute stroke population.  
 
Methods: This study used a cross sectional design. Stroke patients admitted to 
a large city hospital were considered as potential participants. Patients were 
excluded if they had language impairment as identified by the Sheffield 
Screening Test, were aged over 80 years old, had had a previous stroke or 
neurological impairment, and had hearing or sight difficulties that precluded 
them from completing cognitive testing. Recruited participants completed the 
RBANS and a ‘gold standard’ battery of neuropsychological tests. Comparison 
of the two tests were made to identify levels of sensitivity and specificity on 
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global and domain specific cognitive impairment. Analysis was completed to 
identify RBANS optimum cut of scores for identifying global and specific 
cognitive impairment. 
 
Results: 40 participants were recruited. The RBANS demonstrated poor levels 
of sensitivity (52%) and good levels of specificity (100%) for global cognitive 
impairment when using the manual recommended cut off scores. Receiver 
Operating Characteristic curve analysis identified an optimum cut off score for 
RBANS Total scale of 102.5 that provided excellent sensitivity (100%) and 
adequate specificity (83%), and index scores that showed adequate levels of 
sensitivity and specificity to domain specific cognitive impairment with the 
exception of Attention. 
 
Discussion: It was tentatively concluded that the RBANS demonstrated 
acceptable diagnostic validity, though problems were highlighted with the 
Attention index and the use of a test of visual memory within the full battery that 
placed a heavy burden on motor skills. Recommendations were made for 
potential improvements to the study design and procedure, and it was 
suggested that further research into the evaluation of the RBANS as a sensitive 
and specific screening test of post stroke cognitive impairment justified and 
potentially feasible. 
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Abstract 
Background: Cognitive impairment following stroke is common. Current national 
guidelines recommend that survivors of stroke are screened for impairment as 
soon as is practicably possible. Evaluation of commonly used screening tests 
have shown that none have the required levels of sensitivity and specificity to 
perform this task. The RBANS may be a suitable screening test for post stroke 
cognitive impairment. 
Aims: To conduct a pilot study to establish whether extended research was 
justified for evaluating the sensitivity and specificity of the RBANS as a 
screening test for post stroke cognitive impairment. The study objectives were 
to evaluate the RBANS Total Scale and Index score conclusions’ for global and 
domain specific cognitive impairment following stroke, when compared to full 
battery neuropsychological testing. 
Methods: A cross-sectional design was used. Eligible participants were 
recruited from the stroke wards of a large city hospital. Participants were initially 
administered either the RBANS or full battery testing followed by administration 
of the alternative testing with a researcher blind to the previous results. Test 
scores were categorised as impaired or non-impaired on measures of global 
cognitive functioning and specific cognitive domains. 
Results: Analysis of the RBANS Total Scale and Index scores for 40 
participants showed it to have good levels of sensitivity and specificity for global 
and domain specific cognitive impairment when using cut off scores identified 
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by ROC curve analysis, though no optimum score was identified for the 
Attention index. 
Conclusions: The RBANS was a potentially valid test of post stroke cognitive 
impairment, demonstrating good sensitivity and specificity to global and domain 
specific cognitive impairment with the exception of the Attention index. Further 
evaluation of the RBANS was recommended. 
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Introduction 
 
Cognitive problems following stroke are common. It has been reported that up 
to 70% of acute stroke patients present with clinically significant cognitive 
impairment in at least one cognitive domain (1), and that cognitive impairment 
(along with right leg problems) is the most common residual impairment 
following stroke (2). Whilst most stroke research has focused on the physical 
rather than cognitive consequences of stroke (3), cognitive impairment is 
thought to be an important predictor of longer-term difficulties for stroke 
patients, including longer in-patient stays, less responsiveness to treatment, 
and greater loss of independence (4). The National Clinical Guidelines for 
Stroke currently recommends that stroke patients should be screened for 
possible cognitive impairment as soon as is reasonably practicable (5). (See 
extended paper 1.1 - stroke epidemiology). 
 
Screening for cognitive impairments saves the time and cost of administering a 
full battery of neuropsychological tests, which can be administered following 
screening if impairments are detected and require further investigation. 
Screening for post stroke cognitive impairment can contribute to the 
psychological support of survivors of stroke and their families in several 
respects.  Screening can be useful in terms of planning future testing needs, 
monitoring changes in cognitive status over time, and can contribute to 
identifying future support needs and interventions (6). Also, cognitive 
impairment has a significant co-morbidity with post stroke depression and other 
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mood disorders (7), and screening can help inform a wider biopsychosocial 
understanding of an individuals emotional, as well as physical and cognitive, 
response to stroke (8), with interventions for post stroke depression being 
shown to aid functional recovery as well as helping the survivor and their 
families to adjust to the impact of a stroke. (See extended paper 1.3 – Clinical 
Psychology and Stroke). 
 
Ideally, a screening test for should be quick and easy to administer, meaning 
that in practice it can be administered at the patient’s bedside and completed 
within about 10 minutes (9). A screening test can be weighted to identify 
clusters of cognitive impairments to aid a diagnosis (as in dementia screening 
tests), or more globally focused to either screen for the presence or absence of 
cognitive impairment generally or to highlight potential impairments within 
particular cognitive domains. (see extended paper 1.2 cognitive screening). 
 
 
Cognitive domains have been variously categorised and include those of 
memory, executive function, visual perceptual abilities, attention, planning 
movement (praxis), and language (10). (See extended paper 1.4 cognitive 
domains). Cognitive impairment following stroke will depend on the site of the 
blockage or bleed and the extent of the resultant damage. As the stroke can 
occur in any part of the brain, any or all of these cognitive domains can be 
affected with varying degrees of severity, and thus there is no common pattern 
of cognitive impairment following stroke (11). Equally, these domains comprise 
of sub-domains (for instance, memory being sub-categorised in immediate and 
1011, RES, UofN: 4092661, UofL: 08127475, Thesis  
 Page 12 of 169 
delayed, verbal and visual memory, and for a screening test following stroke to 
be effective, it should be able to detect impairment in any cognitive domain, with 
the implication that it should be able to identify impairment of any sub-domain 
(See extended paper 1.5 cognitive impairment and stroke). 
 
A screening test is considered to be diagnostically valid if it demonstrates 
acceptable levels of sensitivity and specificity.  Sensitivity relates to the test’s 
ability to identify all patients with impairment, specificity to the test’s ability to not 
include someone without impairment (4). In practice, there is a trade off 
between sensitivity and specificity, and acceptable rates are generally agreed to 
be 80% agreement or higher for sensitivity, and 60% or higher for specificity 
(12). The cut-off score on a test that gives optimal sensitivity and specificity can 
be calculated using Receiver Operator Characteristic (ROC) curves. The Area 
Under the Curve (AUC) can range from 0.5 to 1, where 1 means 100% 
sensitivity and specificity. However, a test that has low sensitivity in one or more 
cognitive domain may still be acceptably sensitive to global cognitive 
impairment, and thus fail to identify certain groups of people with cognitive 
impairments. Therefore, when evaluating a test for specificity and sensitivity, 
sub-scales as well as total scores need to be evaluated. (see extended paper 
1.6 diagnostic validity / sensitivity & specificity).  
 
Several tests exist to screen for cognitive impairment, though it is important that 
these measures “have been well validated in the populations for which they are 
intended to be used” (10, p790). The Mini-Mental State Examination (MMSE) 
(13) is the most commonly used test to screen for cognitive impairment 
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following stroke, and is the test currently suggested by the Royal College of 
Physicians (5).  
 
Originally designed as a screening test for dementia and delirium, the MMSE 
has come to be used as a screening test for global cognitive impairment (1). 
However, evaluation for its use in screening for post-stroke cognitive 
impairment has shown it to be unsuitable for this purpose. Nys et al (1) 
concluded that with a cut-off score of <24, the MMSE only yielded sensitivity of 
35% for cognitive impairment in acute stroke patients, and an optimal cut-off 
score could not be identified. Further, the only cognitive domain that the MMSE 
showed any sensitivity to was verbal memory (correctly identifying 4 out of 5 
patients), and it failed to identify patients with reasoning disturbances, executive 
dysfunction, and visual perceptual impairments.  
 
The Middlesex Elderly Assessment of Mental State (MEAMS) has also been 
evaluated as a screening test for post-stroke cognitive impairment.  Cartoni and 
Lincoln (4) reported that the MEAMS demonstrated good specificity (100%) but 
poor sensitivity (52%) comparison for total score and overall conclusions for 
impairment, using a cut-off of 3 or more fails. Sensitivity improved to 81% (with 
50% specificity) when using 3 sub-tests to identify cognitive impairment in 
language, perception or memory. Sensitivity to executive functioning 
impairments was reported to be exceptionally poor at 11%.  (see extended 
paper 1.7 evaluation of screening tests). 
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The Repeatable Battery for the Assessment of Neuropsychological Status 
(RBANS) (14) is a potential alternative screening test for post stroke cognitive 
impairment. Originally developed as a screening test for dementia in older 
adults, the RBANS can be administered at a patients bedside, and despite 
taking between 20 to 30 minutes to administer, has been described as being 
well tolerated even by severely ill patients (15). It comprises of 12 sub-tests that 
are combined to form 5 index scores and a total score. The 5 indexes are 
Immediate Memory, Delayed Memory, Visuospatial/Constructional, Language, 
and Attention. (see extended paper 1.8 further description of RBANS). 
 
It has been reported that the RBANS has demonstrated excellent diagnostic 
validity for cognitive impairment in dementia (16) as well as demonstrating good 
validity in screening for cognitive impairment in diagnostically heterogeneous 
groups (16). The RBANS has also demonstrated good validity with differing 
specific populations, including people with schizophrenia (17), adolescent 
psychosis (18), multiple sclerosis (19), traumatic brain injury (20), and end-
stage liver disease (21), though these studies have tended to focus on 
evaluating the RBANS as a measure of overall cognitive impairment, rather 
than identifying impairment in any particular domain.  
 
A number of studies have been undertaken relating to the use of the RBANS 
with stroke patients, though several of these have been completed outside of 
the UK and hence caution should be applied when comparing to these 
conclusions to a UK population, as differences in clinical practice and cultural 
factors may compromise such comparisons. Support for the ecological validity 
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of the RBANS index scores with stroke patients has been reported by Larson et 
al (22). Hoyle et al (23) reported that the RBANS could differentiate the 
hemispheric side of the stroke, and Wilde (24) that the RBANS was a potentially 
valid measure of executive dysfunction in stroke patients, despite not having 
this as an index score. A single case study of a 22 year old psychiatric patient 
who suffered a stroke following screening with the RBANS suggested that the 
RBANS demonstrated sensitivity to pre and post stroke cognitive impairment 
variations (25). However, an evaluation of the sensitivity and specificity of the 
RBANS as a screening test for post stroke cognitive impairment is currently 
missing from the research literature. (see extended paper 1.9 RBANS and 
stroke). 
 
The aim of this pilot study was to to establish whether an extended study into 
the diagnostic validity of the RBANS as a sensitive and specific screening test 
for post stroke cognitive impairment was justified. The study objectives were to 
compare the RBANS scores with full neuropsychological test battery overall 
conclusions for cognitive impairment and non-impairment, to compare the 
RBANS with measures of impairment in specific cognitive domains, and to 
identify RBANS optimum cut-off scores. (see extended paper 1.9 aims). 
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Methods 
 
 
Participants 
 (see extended paper 2.1 sample size) 
 
Participants were recruited from the acute stroke wards of a large inner city 
hospital that admitted approximately 800 people following a stroke per annum. 
Patients were considered appropriate for inclusion in the study if they had 
suffered a stroke. In practice this meant that all patients admitted to these wards 
were considered as meeting the criteria for inclusion in the study. Patients were 
excluded from the study if they were unable to give informed consent (see 
extended paper 2.2 consent), had aphasia (as determined by a score of <15 on 
the Sheffield Screening Test (12) if this test had been administered as part of 
the routine intake assessment, otherwise aphasia was determined on 
consultation with the ward Occupational Therapists), were unable to complete 
the tests due to visual or auditory impairments, or had a neurological, 
psychiatric or dementia diagnosis prior to the stroke. Patients who did not speak 
English were also excluded, as the tests have not been validated for other 
languages, as were patients aged over 80 as several of the battery tests were 
not adequately validated for use over this age. Patients were not explicitly 
excluded if they had had a Transient Ischemic Attack (TIA), though in practice 
these patients were not included as they were not admitted to the acute stroke 
wards from the hyper-acute ward.  Participants were withdrawn from the study if 
they suffered a further stroke or complications.  
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Materials 
All the test score sheets and results were anonymised by replacing the 
participants name with a study ID number. Baseline data, including the 
participants age, gender, and level of education were recorded as per the front 
page of the RBANS, and these were used to compare with norms for identifying 
cognitive impairment on all the tests. The second page of the RBANS 
(Information and Orientation) was not completed as this contained participant 
identifiable information and did not provide scoring information relevant to the 
study. The site of the stroke was documented from the medical record as 
identified by CT scan. RBANS Total Scale and index scores below 69 were 
classed as cognitively impaired as per the manual (14).  
 
The neuropsychological test battery was comprised of selected sub-tests from 
larger test batteries in order to provide the data for global and domain specific 
impairment or non-impairment needed for the study, without subjecting 
participants to extensive and unnecessary (in terms of the study) testing. The 
test battery and selected sub-tests, as well as the assessed cognitive domain, 
are listed in table 1. The tests were completed in the order presented in table 1 
to allow for the time delays required for the testing of delayed memory. A 
measure of language impairment was not included as patients with aphasia had 
already been excluded from the study, though the battery included the short 
NART to estimate pre-morbid IQ and a test of verbal fluency (the COWAT) to 
assess for executive functioning ability. The tests were scored according to the 
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relevant test manuals and published normative data, with classification of 
impairment being made if a participant scored below the 5th percentile on any 
one sub-test. The individual sub-tests were selected to measure sub-domains of 
potential impairment within a particular domain (for instance, the selected tests 
from the VOSP measure separate aspects of Visuospacial ability, namely object 
and space perception, and the Logical Memory and Rey Figure tests, to assess 
verbal and visual memory). This wide ranging approach to battery testing was 
taken to allow for focal impairments to be identified within the context of the 
heterogeneous presentation of potential impairment following stroke, and is in 
line with good practice for exploratory neuropsychological assessment as 
recommended by Lezak et al (7). Consequently, for a screening test of cognitive 
impairment following stroke to be diagnostically valid, it should be sensitive to 
impairment of these differing sub-domains, and so impairment of any single test 
within the full battery resulted in the participant being categorized as CI.  A full 
battery test was considered void if the results were affected by a separate 
cognitive or non-cognitive difficulty. Classification of impairment at the 5th 
percentile was comparable to the scoring procedure used by Nys et al (1), 
though other comparable studies did not report their cut-off points (4, 12). (see 
extended paper 2.3 cut-off point). (see extended paper 2.4 neuropsychological 
test battery). 
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Table 1. Test battery name, selected sub-tests and cognitive domain 
used in the full neuropsychological test battery. 
Test Battery Name  Selected Sub-
Test 
Cognitive 
Domain 
Assessed 
Wechsler Memory 
Scale III (WMS III) 
(26) 
Logical Memory I Immediate 
memory 
Rey Complex Figure 
(27) 
Copy Visuospatial 
WMS III Digit Span Attention 
Rey Complex Figure Immediate Recall Immediate 
memory 
WMS III Letter/Number 
Sequencing 
Attention 
Behavioural 
Inattention Test (BIT) 
(28) 
Star Cancellation Visuospatial 
Visual Object and 
Space Perception 
Test (VOSP) (29) 
Incomplete 
Letters, 
Dot Counting, 
Position 
Discrimination 
Visuospatial 
Controlled Word 
Association Test 
FAS Executive 
function 
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(COWAT) (30) 
Short National Adult 
Reading Test (Short 
NART) (31) 
Full test Pre-morbid IQ 
 
 
WMS III Logical Memory II Delayed 
memory 
Rey Complex Figure Delayed Recall Delayed 
memory 
Modified Card Sorting 
Test (MCST) (32) 
Full test Executive 
function 
Hayling and Brixton 
Test (33) 
Brixton Spatial 
Anticipation Test 
Executive 
function 
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Procedure 
Patients considered eligible for inclusion in the study were approached by a 
member of the healthcare team (usually a ward staff nurse) for potential 
participation in the study and given a patient information sheet. After 48 hours, 
informed written consent to participate was taken by a member of the research 
team and the first set of tests (either the RBANS or full battery) was completed.   
 
Potential participants were identified through weekly meetings between the 
research team and ward staff, and approach for participation was made as soon 
as was practicably possible following admission to the ward from the hyper-
acute ward. Both the researchers were present on the wards for two days per 
week to allow administration of the tests to be completed as closely as possible 
to each other, with an expectation that this should not be longer than five days, 
in order to minimize the effect of potential change in cognitive status due to 
spontaneous recovery. Initial administration of either the RBANS or full 
neuropsychological battery was alternated to control against order bias. 
Researchers were unaware of the results from previously administered tests to 
control against investigator bias.  
 
After completion of either the RBANS or full battery, the participant was 
informed that they would be approached by a separate member of the research 
team to complete the alternate set of tests. The RBANS took between 20 to 30 
minutes to complete and was administered at the participant’s bedside. The full 
battery testing took between 1 to 1½ hours to complete, and was completed in a 
separate room if this was available and appropriate. These tests were then 
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scored and filed securely. If the participant had been discharged, then an 
appointment was made with the participant to complete the testing at a 
convenient location. If the participant had suffered a change in their condition 
between test administration then continuation in the study was discussed with 
the healthcare team. The chief investigator collated the results of all the tests at 
the end of each week. A summary report was later completed by the research 
team and filed in the participants’ notes. (See extended paper 2.5 further details 
of research procedure).  
 
Statistical analysis  
Data was analysed using the Predictive Analytics Software (PASW) progamme 
version 17. Data was coded as indicating participants as clinically impaired (CI) 
or non-clinically impaired (NCI), based on the cut-off scores outlined above. 
Sensitivity and specificity were calculated by comparing agreement and 
disagreement between two tests of CI/NCI. Positive predictive values (PPV) and 
negative predictive values (NPV) were also calculated.  
 
Comparison were made between RBANS total score and battery test total 
scores and between index scores and battery test conclusions for executive 
function, visuospacial perception, attention, immediate memory, delayed 
memory and language.  
 
Receiver Operating Characteristic (ROC) curves were calculated for the 
RBANS Total scale/Total CI/NCI as measured by the test battery, and for the 
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RBANS index/Test battery specific conclusions, to identify RBANS optimum cut-
off scores in relation to sensitivity and specificity.  
 
Ethical Approval 
Ethical approval was granted by a local NHS Research Ethics Committee, the 
University of Lincoln, and site specific NHS R&D departments. No risks to 
participants, investigators, or NHS trusts, resulting from taking part in this study, 
were identified. (see extended paper 2.6 ethical approval). 
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Results 
(See extended paper 3.1 Normality of Distribution) 
Demographic details 
During the recruitment phase of the study, 390 patients were admitted the 
hospital stroke wards of whom 146 (37%) met the study inclusion criteria and 
were approached to participate. A total of 47 patients (32% of patients who met 
the inclusion / exclusion criteria) consented to participate, of which 7 15%did not 
complete the full testing as 3 were discharged before completing all tests, one 
had visual difficulties, one became unwell during testing, and 2 declined to 
participate further. Testing took on average one hour to complete the full battery 
and 20 minutes for the RBANS, and did not appear to be a factor in patients’ 
decisions regarding participation or participants’ withdrawal from the study, Of 
the 40 participants, 25 (62%) were male. Age ranged from 30 to 80 years (mean 
age 68.65, SD 12.91) and years of education from 8 to 16 (mean 10.70, SD 
3.15).  Twenty-two (55%) participants had a right hemispheric stroke, 15 
(37.5%) had a left hemispheric stroke and 2 (10%) had a bilateral stroke. 
Ischemia was the cause of stroke in 35 (87.5%) of participants and 
haemorrhage the cause in 4 (10%) participants: hemisphere and cause was not 
recorded for one (2.5%) participant. The stroke was classified as total anterior 
circulation syndrome in 14 (35%) participants, partial anterior circulation 
syndrome in 9 (22.5%), posterior circulation syndrome in 1 (2.5%), and lacunar 
circulation syndrome in 13 (332.5%), with classification not recorded for 3 
(7.5%) participants. The mean interval between onset of the stroke and 
completing the testing process was 22 days (SD 17) and the mean interval 
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between the first and second test was 3 days (SD 4). (See extended paper 3.2 
demographic details). 
 
Descriptive details 
The conclusions of the full neuropsychological test battery identified 33 
participants (82.5%) as having an impairment in at least 1 cognitive domain. 
More specifically, 60% of participants were identified as having an impairment in 
visuospatial abilities, 60% in executive functioning, 52% in attention, 47.5% in 
delayed memory, 27.5% in immediate memory, and 20% in language. When 
using the suggested cut-off score of 69 (13) on the Total Scale index, the 
RBANS identified 17 participants (42.5%) as having a cognitive impairment. 
When using the RBANS individual index scales to identify whether a participant 
had an impairment in one or more cognitive domain, this rose to 27 participants 
(67.5%) being identified as cognitively impaired. Specifically, the RBANS 
identified 50% of participants as having an impairment in visuospatial abilities, 
40% in attention, 40% in delayed memory, 35% in immediate memory, and 15% 
in language. (see extended paper 3.3 further descriptive details). Several 
participants were categorised as cognitively impaired in more than one cognitive 
domain: the number of cognitive domains identified as impaired by the RBANS 
(at the manual suggested cut off score) and full battery (excluding executive 
functioning) per participant is summarised below in table 2. (Table 2 presents 
the total number cognitive domains for participants identified as impaired / non-
impaired as opposed to a running total). 
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Table 2. Number of cognitive domains categorised as impaired per participant 
for RBANS and Full Battery conclusions.  
Number of 
participants identified 
Number of 
domains 
impaired RBANS Full Battery 
0 13 7 
1 6 10 
2 8 8 
3 6 7 
4 4 3 
5 3 5 
 
  
 
Diagnostic validity  
(see extended paper 3.4 diagnostic validity using recommended cut-off scores).  
Analysis of the RBANS conclusions for impairment when using cut-off scores of 
<69 showed that the only measure to provide an acceptable level of sensitivity 
and specificity was for global conclusion of cognitive impairment when identified 
by impairment on 1 or more index score (sensitivity = 81 [95%CI =64-92], 
specificity = 100 [95%CI = 56-100]). All other measures identified either 
acceptable levels of sensitivity or specificity, but combined levels could not be 
identified. 
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ROC analysis suggested that the RBANS Total Scale was able to identify global 
cognitive impairment (AUC = 0.96, p<0.001), and the RBANS Indexes were 
able to identify impairment in all the specific cognitive domains. The 
Visuospatial/Constructional Index had the highest diagnostic accuracy (AUC = 
0.97, p<0.001) when compared to full battery visuospatial domain specific 
conclusions, followed by: Delayed Memory (AUC = 0.82, p<0.001), Immediate 
Memory (AUC = 0.82, p<0.002) and Attention (AUC =0.76, p<0.01). RBANS 
Total Scale showed the highest diagnostic accuracy to executive function 
impairments (AUC = 0.89, p<0.001) and  Language the lowest (AUC = 0.78, 
p=0.03). RBANS optimum cut-off scores for sensitivity and specificity were 
identified by ROC analysis for global and domain specific cognitive 
impairments, when compared to the full battery conclusions, and are presented 
in table 3 along with positive and negative predictive values. Acceptable levels 
of sensitivity, specificity, PPV and NPV are highlighted. (see extended paper 3.5 
Cross Tabulation and 3.6 ROC and AUC conclusions) 
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Table 3. Sensitivity, specificity, positive and negative predictive values for 
RBANS conclusions based on ROC identified optimum cut-off scores 
RBANS 
Index 
(Cut-off 
score) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive 
Predictive Value 
(95% CI) 
Negative 
Predictive 
Value (95% 
CI)  
Total Scale 
(102.5) 
100% 
(87-100) 
83% 
(30-94) 
94% 
(79-99) 
100% 
(46-100) 
Immediate 
Memory 
(79.5) 
82% 
(48-97 
72% 
(53-87) 
53% 
(29-76) 
91% 
(70-98) 
Visuospatial 
(88) 
100% 
(82-100) 
75% 
(47-92) 
88% 
(66-95) 
100% 
(70-100) 
Attention 
(86.5) 
86% 
(63-96) 
47% 
(25-70) 
64% 
(44-81) 
75% 
(43-93) 
Delayed 
Memory 
(90.5) 
94% 
(72-99) 
61% 
(39-81) 
69% 
(48-85)  
93% 
(64-100) 
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Discussion 
 
A superficial review of the results would suggest that the RBANS has strengths 
and weaknesses as a diagnostically valid test for the screening of post stroke 
cognitive impairment. When using the manual suggested cut off scores (15), the 
RBANS was poor at discriminating between overall impairment and non-
impairment on the total scale and on domain specific impairment or non-
impairment on any index. However, the test did demonstrate adequate 
sensitivity and specificity to overall cognitive impairment when an impairment 
was identified on one or more indexes, indicating that the RBANS may have 
been measuring similar constructs to the full battery but labelling them under 
different domains. 
 
Using ROC curve analysis, cut off scores were identified that gave good to 
excellent levels of sensitivity and specificity for global and domain specific 
cognitive impairment with the exception of attention, which demonstrated 
adequate sensitivity but poor specificity. It is possible that this may have been 
due to the RBANS assessing attention using ‘Coding’, which incorporates motor 
skills and may have disadvantaged participants who had physical difficulties 
resulting from their stroke, and was not picked up by the full battery attention 
tests of Digit Span and Letter/Number Sequencing. It should also be noted that 
the ROC analysis identified an RBANS optimum cut off score of 102.5 on the 
total scale, which is at approximately the 51st percentile of the normative 
sample. This point was identified as it gave the optimum balance between 
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sensitivity (100%) and specificity (71%) with sensitivity being preferred over 
specificity. However, ROC analysis identified that a cut off score of 83.5 
resulted in adequate sensitivity (82%) and excellent specificity (100%), with this 
cut off point being at slightly greater than 1 sd below the mean, and equivalent 
to the RBANS optimum cut off point reported by Duff et al (16). An explanation 
for the identification of 102.5 as the optimum cut off point would be that the low 
number of participants identified as NCI overly inflated the cut off point needed 
to exclude those without impairment, and future research would need to ensure 
that an adequate number of NCI participants were identified to allow for 
confidence in the ROC identified cut off point.    
 
The Total Scale score demonstrated excellent diagnostic accuracy for executive 
function impairment, perhaps reflecting current thinking that executive 
functioning is not a homogenous construct but is related to several cognitive 
functions (33), and hence would not be identified on a single RBANS index but 
could be identified through the overall (Total Scale) conclusions. However, the 
clinical utility of the RBANS in screening for executive functioning impairment is 
severely limited by it not having a separate index for this domain: all that can be 
concluded from a low score on the Total Scale would be that further evaluation 
of executive functioning would be necessary. This could potentially be mitigated 
against in clinical practice by administering a short test of executive functioning 
ability (such as the COWAT) alongside the RBANS, though this would increase 
the duration of screening. 
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The Positive and Negative Predictive Values suggested that confidence in 
identification of an impairment or non-impairment was excellent for the Total 
Scale at a cut off score of 102.2, and for Visuospatial/Constructional impairment 
at a cut off score of 88. None of the other indexes demonstrated consistently 
high levels of confidence for both positive and negative impairment conclusions, 
and the Immediate Memory index was especially poor in its negative 
conclusions. This could be related to the higher prevalence of global and 
Visuospatial impairments, though at 53% the Immediate Memory PPV was 
barely better than chance. Even with these limitations taken into account, based 
on these findings the RBANS would be a suitable screening test for post stroke 
cognitive impairment, and offered superior diagnostic validity to that reported for 
the MMSE (1) and the MEAMS (4). (see extended paper 4.1 – further 
interpretation of results) 
 
There are several limitations to this study. Firstly, the sample was only taken 
from those patients who were admitted to the stroke rehabilitation wards and as 
such it did not represent those patients who were discharged within 48 hours of 
admission to hospital. This would therefore limit the generalisability of these 
results for the overall stroke population and would significantly limit the validity 
of these conclusions for people who had a TIA, though the results would still be 
applicable to acute in-patient settings where the routine screening of post stroke 
cognitive impairment usually occurs. Secondly, whilst careful consideration went 
into the development of the full battery of neuropsychological tests, this battery 
may not have identified all potential cognitive impairments, as to standardise the 
test battery to cover all potential impairments would have made the testing load 
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intolerably high. However, conducting the pilot did allow for evaluation of the full 
battery, and several alterations would be recommended, including replacing the 
Rey Complex Figure as a test of visual memory with a non-motor task, as this 
test was largely invalidated for participants with physical impairment. Thirdly, 
the RBANS identified 6 participants as being impaired on the Language index, 
despite aphasia being an exclusion criterion. This was due to the SST being 
infrequently administered as part of the routine intake testing, and exclusion for 
aphasia being based on ward staff consensus rather than formal measures. 
Consequently, it is possible that the validity of test results may have been 
compromised in that participants may have produced a score indicating 
cognitive impairment on a particular domain when infact the test result was due 
to receptive or expressive difficulties. Whilst language impairment would have 
applied to both the RBANS and full battery testing (and hence would effect both 
test conclusions) it may be that for these participants the clarity of the test 
administration instructions was more pertinent than the domain under 
examination thus introducing an extraneous variable, and it would be 
recommended that for an extended study, the SST be administered before 
proceeding with the testing. Finally, a further limitation in the interpretation of 
these results was the large confidence intervals due to the small sample size 
and small number of non-cognitively impaired participants.  
 
Even with these limitations, the confidence intervals of this study were 
comparable with some of those that have been reported in other studies of 
screening for post-stroke cognitive impairment. Cartoni and Lincoln (4) for 
instance reported   sensitivity of the MEAMS for post stroke cognitive 
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impairment at 52% with a 95% confidence interval of 32 to 71% (though this still 
falls short of the 80% recommended cut off point), and sensitivity of 100% with 
a 95% confidence interval of 29 to 100%.  Nys et al (1) did not report confidence 
intervals, and had a smaller sample size than this study at 34 participants. The 
samples sizes of these studies also reduced considerably when exploring 
domain specific impairments, with Nys et al (1) for instance, reporting 5 
participants identified by full battery testing as having visual memory deficits. 
Given that other studies have suggested that the RBANS has excellent 
diagnostic validity amongst heterogeneous populations (16), which is reflected 
in the impairments identified within this study, and that it has demonstrated 
ecological validity post stroke (22) as well as sensitivity to pre and post stroke 
cognitive impairment (24) (including executive dysfunction [24]), this study 
contributes to the body of literature on post stroke cognitive impairment by 
suggesting that its use as a screening test may be justified when contrasted 
with other comparable research.      
 
 
Recruitment of stroke patients into research projects has been reported as 
having a consistently low consent rate, with recruitment rates of eligible patients 
being reported at between 10 and 50% (34), which is comparable to the 
consent rate of 32% of this study.  There were several factors that impacted on 
the study’s recruitment rate including the fact that several studies were being 
conducted on the acute stroke wards concurrently to this one, and some 
potential participants reported this as being a reason for non-participation. 
However, no potential participants explicitly cited the time commitment required 
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as a reason for non-participation, and no participants withdrew from the study 
due to this; many of the participants reported that they had enjoyed the process, 
and the administration of the RBANS appeared to be well tolerated, in line with 
other research observations (15). It should be noted however that voluntary 
consent means that recruited participants may not be representative of the 
acute stroke population, in that people may have been more likely to participate 
if they felt well enough to, were motivated or had confidence in their cognitive 
abilities, or were not incapacitated by other factors including post-stroke 
depression. Information on non-recruited patients was not recorded for this pilot, 
and it would be recommended that future research take these factors into 
account to allow for greater confidence (or otherwise) in the generalisation of 
results.(see extended paper 4.4 – critical reflection). 
 
 
It is worth noting that the prevalence rates of overall impairment and domain 
specific impairment conclusions of the full test battery in this study were 
comparable with those reported previously (1,4,12). Whilst there is a relatively 
wide range of reported prevalence rates, and as such it may be difficult to draw 
conclusions, this could potentially suggest that the sample in this study was 
comparable to those in previous research, and therefore the conclusions could 
have some level of generalisability to the wider acute stroke population.  
 
The results presented here tentatively suggest that the RBANS is potentially a 
sensitive and specific screening test of post stroke cognitive impairment, both 
as a measure of global impairment and as a screening test for particular 
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cognitive domains. Given the almost ubiquitous prevalence of post stroke 
cognitive impairment (5) it could be argued that the RBANS has clinical utility in 
post stroke psychological support beyond that of routine screening. Given that 
cognitive impairment following stroke can spontaneously remiss over a 
relatively short time period (10), the RBANS could be used in clinical practice to 
monitor change in cognitive status and in predicting which people may need 
more detailed assessment. With diagnostic confidence in the test results, the 
information gathered from screening could be useful in informing a wider 
formulation of the idiosyncratic impact of stroke and in exploring the meaning of 
this for the patient, family members and other carers, and thus help to inform 
interventions, either directly with the survivor and their family or indirectly with 
other care staff, tailored to individual compensation approaches and coming to 
terms with the consequences of stroke (9). Also within a wider formulation, it 
could be useful in predicting which survivors may benefit from focused 
individual intervention for post-stroke depression (8). (See extended paper 4.2 – 
Implications for clinical psychologists  working in stroke services). As the results 
presented here suggest that the RBANS may demonstrate acceptable 
sensitivity and specificity in screening for post stroke cognitive impairment, 
further evaluation of the RBANS would be justified, with a sample size based on 
the prevalence rates for both global and domain specific cognitive impairments 
identified from this pilot study to allow for increased confidence in the 
conclusions.  (see extended paper 4.4 – Feasibility of extended study and 4.5 – 
future research). 
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1.     EXTENDED BACKGROUND 
 
1.1     Stroke epidemiology 
 
Injury to the brain can result from several causes including perinatal disorder, 
brain tumour, infection, demyelinating disease, cerebrovascular disease 
(including stroke), trauma, epilepsy, and neurodegeneration (Cairns, 2004) as 
well as a consequence of medication and toxins (Powell, 2004).  These injuries 
can result in various degrees of severity (including death) affecting a person’s 
physical, emotional, cognitive, and/or behavioural functioning (Evans, 2003). A 
person who has suffered a stroke might experience problems in any or all of 
these areas, and a problem in one area can lead to difficulties in another, such 
as physical difficulties leading to a depressed mood. Consequently, stroke 
management and care should be a collaboration between professionals of 
various disciplines (Fawcus, 2000) and clinical psychology has a significant role 
to play in this interdisciplinary cooperation.  
 
A stroke is caused by an interruption to the blood supply of the brain. This 
interruption can be caused either by an artery becoming blocked (thrombosis or 
embolism) and leading to tissue death (infarction) in the brain, which is known 
as an ischaemic stroke, or bleeding from an artery resulting in cell damage and 
death from the haemorrhage (Skilbeck, 1992). Bleeding into the brain tissue is 
called a intracerebral haemorrhage, and a bleed over the brain’s surface a 
subarachnoid haemorrhage (Hankey, 2002). Approximately 90% of strokes are 
caused by infarction and 10% by haemorrhage (Celani et al, 1992), though it 
can be difficult to identify an accurate cause in approximately 20% of cases 
(Wolfe, 2000). The Oxford Community Stroke Project subdivided cerebral 
infarction into four types based on a combination of cause and site of the 
infarction: the categories are total anterior circulation syndrome (TACS), partial 
anterior circulation syndrome (PACS), posterior circulation syndrome (POCS) 
and lacunar circulation syndrome (LACS) (Bamford, Sandercock, Dennis, Burn 
& Warlow, 1991). Risk factors for stroke include age greater than 75 years, high 
blood pressure, atrial fibrillation, smoking and taking oral contraceptives (Wolfe, 
2000).   A transient ischaemic attack (TIA) initially presents as similar to a 
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stroke, though, as its name suggests, is short lived, with any symptoms 
(including cognitive impairment) improving within 24 hours (Skilbeck, 1992).   
 
Stroke is a major cause of death and disability affecting up to 216 per 100,000 
population in the UK each year (Mant, Wade, & Winner, 2004). In England there 
are currently more than 900,000 people living with the after effects of stroke, 
with approximately half of these dependent on others for help with activities of 
daily living (The National Collaborating Centre for Chronic Conditions, 2008). 
Incidents of stroke increase with age, with approximately half occurring in 
people aged over 75, and consequently the number of stroke patients will 
potentially continue to increase as a result of an increase in the longevity of the 
population (Hankey, 2002). Race and ethnicity appear to influence the 
incidence and prevalence of stroke, and geographical location the mortality rate, 
with mortality rates ranging from 249 deaths per 100000 population in Bulgaria 
to 27 per 100000 population in Switzerland (Hankey, 2002). Men and women 
appear to be affected equally (Hankey, 2002). 
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1.2    Cognitive Screening 
 
Ideally, a cognitive screening test should be brief, and simple to administer and 
score by clinicians without specialist neuropsychological training (Blake et al, 
2002). Brief screening tests for cognitive impairment may be useful for many 
differing purposes. Cullen, O’Neill, Evans, Coen and Lawlor (2006) cite several 
uses including aiding General Practitioner assessments, screening programmes 
of large scale communities, the identification of profiles of impairment specific to 
particular diagnoses, aiding differential diagnoses and identifying cognitive 
areas or patients for further assessment. Each of these uses will determine the 
design, content and scope of the screening tool, and given the plethora of 
screening tests available, it is important to match the test’s output to the 
purpose of screening. This study is principally concerned with the diagnostic 
validity of the RBANS as a test to identify cognitive impairments following stroke 
that require further, detailed assessment. Detailed neuropsychological 
assessment has been highlighted as an important aspect of the management of 
stroke (Royal College of Physicians, 2008), though this can be costly, both in 
terms of finance and time, and effective screening can identify where these 
resources can be best utilised (Blake et al, 2002).  
 
Lezak, Howieson and Loring (2004) point out that the use of any cognitive 
screening test should always be done with the limitations of the test being borne 
in mind. Even the best validated screening tests will not be able to identify every 
possible cognitive impairment nor every person with an impairment, unless it 
has 100% sensitivity. This in itself can be problematic in that in order to have 
such a high sensitivity rate the test is also likely include a high proportion of 
people who do not have an impairment. That is to say that with a very low cut-
off rate, the test may have 100% sensitivity, but if all tests are positive it will 
have 0% specificity (though it will have included all people with the disorder) 
(Spitalnic, 2004). The same is true if reversed for specificity, in that it can be 
100% specific by having a very high cut-off point, but will also excluded all those 
who do have the disorder. The best that can be concluded for a person who has 
no impairments identified is that they scored within normal limits at the particular 
time that the test was taken (Lezak, Howieson & Loring 2004).  
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1.3 Clinical Psychology and Stroke 
 
Cognitive impairment following stroke is a predictor of poorer long-term 
functional outcome (Denti, Agosti & Francheschini, 2007) with at least 35% of 
stroke survivors having significant cognitive impairment at 6-month follow-up 
(Tatemichi, Desmond, Stern, Paik, Sano & Bagella, 1994). It is estimated that 
75% of stroke survivors with cognitive impairment present with clinically 
significant mood disorders in the acute stage, as do 42% of stroke survivors 
without cognitive impairment (Saxena, 2006), with an estimated 35% of all 
stroke survivors presenting with depression following the acute stage (Hackett, 
Yapa, Parag & Anderson, 2005).  
 
Evidence for psychological intervention following stroke is limited by a lack of 
high-quality research (Royal College of Physicians, 2008), and much of the 
support for their use with stroke survivors is extrapolated from research 
evidence for interventions for mood disorders within the general population 
(British Psychological Society [BPS], 2010). Watkins et al (2007), in a large 
randomised controlled study, reported that Motivational Interviewing led to a 
statistically significant improvement in mood following stroke, though it did not 
show an improvement in the functional recovery of stroke survivors. Cognitive 
Behavioural Therapy (CBT) has demonstrated mixed results in treating 
depression following stroke (Lincoln & Flannaghan, 2003) and more research is 
needed. There is even less research into psychotherapeutic interventions for 
post-stroke anxiety, though there is tentative evidence to suggest that CBT may 
be effective (Soo & Tate, 2007). Despite the lack of research evidence, 
psychological intervention has been identified as an important factor in helping 
people recover from stroke (BPS, 2010) and is recommended in the National 
Clinical Guidelines for Stroke (Royal College of Physicians, 2008).  Equally, 
whilst there is little evidence to suggest that re-training of lost cognitive abilities 
is effective (BPS, 2010) compensation approaches have been shown to aid 
functional recovery and to help a person adjust to the consequences of a stroke 
(Lincoln, 2005), and the identification of cognitive impairment is an important 
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factor in planning for hospital discharge and in planning and delivering multi-
disciplinary interventions (Royal College of Physicians, 2008). 
 
The impact of a person having a stroke can be devastating for families and 
carers, with psychological problems and carer strain being commonly reported 
(Draper & Brockelhurst, 2007). Clinical psychologists can play an important role 
in supporting carers to support the survivor of a stroke, which can not only help 
to maintain the psychological well-being of the survivor (Morris, Robinson, 
Raphael & Bishop, 1991), but also reduces the financial burden on health and 
social service providers (Hirst, 2002). 
 
The National Stroke Strategy (Department of Health, 2007) has made several 
service recommendations specifically pertaining to the provision of 
psychological services for survivors of stroke and their families: 
 
“Screening (to) identify those who can benefit from access to a broad 
range of mental health and psychological services” (p43) 
 
“Services need to develop long-term psychological and emotional 
support, with co-ordinated programmes starting with psychological support in 
hospital” (p43). 
 
“Carers are also vulnerable to difficulties in coping and depression 
…and…are entitled to an assessment in their own right” (p44). 
 
From this document, the British Psychological Society (BPS, 2010) identified 
eleven quality markers where a clinical psychology could significantly contribute 
to post stroke survivor care. These were: Managing Risk (Quality Marker 2), 
Information advice and support (QM3), Assessment (QM8), Treatment (QM9), 
High quality specialist rehabilitation (QM10), End of life care (QM11), Long term 
care and support (QM13), Participation in community life (QM15), Return to 
work (QM16), Leadership and skills (QM18), and Research and audit (QM20). 
Within this context, screening for post stroke cognitive impairment plays a 
relatively small role in the possible contribution clinical psychologists could play 
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in providing psychological support for survivors of stroke, and in practice most 
screening would be performed by a member of the ward team (at the hospital 
where this current study was completed, screening for post stroke cognitive 
impairment was conducted by the ward Occupational Therapists). Where 
clinical psychologists do have a role in the screening of post stroke cognitive 
impairment is in the interpretation of the results. Screening, by its nature, 
compares a persons performance on the test against the performance of other 
people (either drawn from the general population or from a particular diagnostic 
group) to decide whether a person has scored at a significant point to conclude 
that an impairment is present, Clinical psychologists are equally interested in 
how that persons performance on the screening test compares with, and relates 
to, other aspects of that persons presentation. In isolation, a persons screening 
result is relatively meaningless, and for it to have any ecological value it should 
be embedded within a wider formulation that takes into account biological, 
psychological and social factors (Darby & Walsh, 2005). From this 
biopsychosocial formulation an understanding can begin to be developed of not 
only what the cognitive and functional consequences of having a stroke might 
be for an individual, but also an understanding of what the consequences might 
mean for the survivor and their families or carers. From this, interventions can 
be tailored to address the survivors idiosyncratic needs, which might include 
further neuropsychological testing to assess in greater detail the presence or 
otherwise of cognitive impairment, and may also include offering support and 
advice to the client, family or support team on managing or compensating for 
any identified impairments, as well as providing psychotherapeutic interventions 
for the survivor and/or their family in coming to terms with the stroke and its 
consequences and in treating post stroke depression or other related mood 
disorders.  
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1.4     Cognitive Domains 
 
Cognitive domains have been variously described, but consensus appears to be 
to categorise them as domains of memory, language and communication, 
executive function, voluntary movement, visuospatial perception and attention, 
and number processing and calculation, each of which contain sub-categories 
(e.g. semantic and episodic memory). These domains are briefly described, 
along with their corresponding impairments. 
 
Memory (from Evans, 2004) is not a unitary concept (either psychologically or 
anatomically), but variously sub categorised to including short term (or working) 
and long term memory, declarative (explicit, utilising conscious recollection) and 
non-declarative (implicit, such as priming and classical conditioning), semantic 
(context independent factual information) and episodic (context dependent, 
such as personal experiences), as well as a distinction being made between 
recall (recollection in the absence of the thing to be remembered) and 
recognition (material matched with a memory). Also, prospective memory refers 
to the ability to remember to do things in the future, which also involves co-
ordinating planning and attentional abilities. 
 
Any of these memory systems can become impaired, though disorders of short 
term and semantic memory are rare. With regard to memory impairment, a 
further distinction is made between anterograde memory (the learning of new 
information following the onset of impairment) and retrograde memory 
(memories laid down before the onset of impairment). The commonest memory 
disorder is amnesic syndrome where working, semantic, and implicit memories 
generally remain intact, whilst retrograde memory can be variably affected, and 
anterograde memories are impaired. 
 
Language and communication (from McKenna, 2004) has been recently 
understood in terms of models of serial and hierarchical stages of information 
processing. A differentiation is made between comprehension and expression, 
with comprehension described as inputting into the semantic system, and 
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expression outputting from it. Distinctions are made (though similar models 
used) between visual and auditory communication, and non-verbal language.  
 
Collectively know as aphasia, impairments include difficulty in using correct 
grammar and syntax, problems with aural and written comprehension, difficulty 
in articulation, and problems with word finding. 
 
Executive function (from Burgess & Alderman, 2004) is described as the ability 
of a person to organise their ability to identify goals, and to follow and adapt 
plans to achieve them in the face of competing demands and circumstances. 
 
Impairments are known as executive dysfunction and collectively as 
dysexecutive syndrome, of which there are many symptoms, with the 
commonest being difficulty in planning, distractibility, lack of insight, poor 
decision-making and social unconcern. 
 
Voluntary movement (from Goldstein, 2004) is the ability to carry out purposeful 
and/or learned voluntary movement. 
 
Impairment is known as apraxia, and is identified when a person is unable to 
perform such movements despite having normal motor skill and comprehension 
of what carrying out the movement involves. Apraxia is often sub-categorised 
into ideomotor apraxia (incorrect selection and sequencing of movements), 
ideokinetic apraxia (inability to coordinate fine and precise movements), and 
ideational apraxia (difficulty in using objects for their correct purpose despite 
being able to name the object) 
 
Visuospatial perception (from Manly & Mattingley, 2004) refers to the structure 
of the visual system including the visual field and higher level visual processing.  
 
Most commonly reported impairment of visuospacial ability is unilateral spatial 
neglect, which is defined as ‘a difficulty in detecting, acting on or even thinking 
about information arising from the side of space opposite the damaged 
hemisphere’ (p229). Also included are disorders of object recognition (agnosia).  
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Attention (from Manly & Mattingley, 2004) refers to the ability to concentrate and 
‘to stay on task’, and whilst being difficult to operationalize and assess, are 
often reported as distractibility and absent-mindedness. 
 
Number processing and calculation (from McNeil, 2004) refers to the ability to 
understand and manipulate numbers, including comprehension and production 
of written and spoken numbers both named and using numerals, and is 
considered a separate system to language, as patients with aphasia usually 
have preserved number processing and calculation abilities. 
 
Number processing and calculation has received much less interest than other 
areas of cognitive impairment though it can have an enormous impact on 
everyday tasks such as managing money, using telephones, or knowing time 
and dates. It is not routinely assessed for by cognitive impairment screening 
tests (including the RBANS) and has received no apparent attention in the 
evaluation of these screening tests for post stroke impairments.  
 
 
These cognitive domains are theoretically hypothesised concepts or constructs, 
the existence of which cannot be confirmed in any absolute way (Willmes, 
2003). To be of any value (especially in terms of psychometric testing) these 
constructs should demonstrate acceptable construct validity (i.e. the extent to 
which the hypothesised implications of the theoretical construct are reflected in 
other research findings), and be adequately operationalised (essentially, how 
the construct is defined) (Barker, Pistrang, & Elliott, 2002). 
 
Whilst most neuropsychological text books are focussed around the concept of 
cognitive domains (and often without commenting on their construct validity), 
not everyone agrees that these constructs are valid. Chaytor, Schmitter-
Edgecombe & Burr (2006) for example, reported that four commonly used tests 
of executive functioning failed to predict participant’s everyday executive 
functioning ability. This could of course be a reflection of the tests’ lack of 
ecological (real life) validity, rather than a problem with the validity of the 
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construct of executive function. Though if, as the above description of construct 
validity suggests, construct validity derives at least in part from being able to 
measure hypothesised consequences of the construct, then it could be equally 
argued that the lack of validity lies with the construct itself rather than the tests.  
However, Lezak, Howieson and Loring (2004) concluded that questions 
regarding the validity of psychometric testing (and thus the validity of the 
theoretical constructs underpinning them) had been at least partially answered, 
‘almost always in the affirmative’ (p11), by the body of research literature. 
Interestingly, Miller (1992) argued that construct validity is not an essential 
feature of psychometric tests when they are used for diagnostic purposes; the 
importance is to whether the test can reliably discriminate between the 
presence and type of impairment.  
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1.5    Cognitive Impairment and Stroke 
 
Cognitive impairment refers to impaired functioning in aspects of one or more 
cognitive domains. Any cognitive impairment following stroke will depend on the 
site of the blockage or bleed and the extent of the resultant damage, and as the 
stroke can occur in any part of the brain, any (or even all) of the cognitive 
domains listed above can be affected with varying degrees of severity, and thus 
there is no common pattern of cognitive impairment following stroke (Skilbeck, 
1992).  
 
An injury to the brain may cause global cognitive impairment, in that there is a 
generalised impairment in cognitive functioning, or the impairment may be focal, 
affecting a discrete cognitive domain (Lezak, Howieson & Loring, 2004). In most 
cases, cognitive impairment following stroke is focal in nature due to an infarct 
affecting the local area: a haemorrhage stroke is less common and more like to 
cause global impairment (Hankey, 2002). There are several cognitive 
impairments that have become associated with stroke due to the regularity of 
their occurrence, of which Skilbeck (2003) suggests that aphasic problems and 
left sided neglect are the most common. However, a review of 3 recent research 
papers (Nys et al, 2005, Blake, McKinney, Treece, Lee, & Lincoln, 2002, and 
Catroni & Lincoln, 2005) suggests that overall, executive functioning was the 
most commonly identified cognitive impairment (when using a full battery of 
psychometric tests). The cognitive impairments identified in these studies by full 
battery neuropsychological testing are summarised below in table 4. It should 
be noted that these figures only represent patients well enough to participate 
and who gave their consent, and do not include figures for impairments of 
movement or calculation. Where separate tests have measured the same 
domain, it has not been possible to identify whether participants are included in 
both scores, so a range has been given (and note that this does not necessarily 
imply that there is a discrepancy in the construct validity, only that the tests 
measure differing aspects, or sub-categories, of the same cognitive domain).  
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Table 4. Summary of percentage of stroke patients identified with cognitive 
impairment by full battery neuropsychological testing. 
 
As table 4 shows, there is a wide range of reported prevalence rates for 
cognitive impairments following stroke. This may be due to differences in 
samples sizes, research methodologies, and/or measures used in the full 
battery testing. Cartoni et al (2005) excluded patients with a diagnosis of 
aphasia, which would not only bias the prevalence rate for language impairment 
but may also have had an effect on the other battery results as the sample was 
made up from a potentially different population of stroke patients as reported by 
the other two studies. Likewise, neither Blake et al (2002) nor Nys et al (2005) 
reported on how they controlled for the effects of aphasia on the completion of 
tests for other cognitive domains (as a difficulty in understanding the test 
instructions could lead to spurious results unless understanding was 
ascertained).  
 
There were also significant differences between the three studies in the duration 
between the occurrence of the stroke and the administration of the full battery 
testing. Blake et al (2002) reported that full battery testing was administered 
within three months of admission, Cartoni et al (2005) between one and eighty-
 
 
Study 
 
 
Cognitive 
Domain 
Nys et al 
(2005) 
(N=34) 
Blake et al 
(2002) 
(N=112) 
Cartoni et 
al 
(2005) 
(N=30) 
Executive 
Function 
32-47 52 86 
Perception 21 26-51 60 
Memory  12-15 42-56 46 
Language 26 40 13 
Total % of 
those with 
at least 1 
impairment 
 
70 
 
Not 
reported 
 
Not 
reported 
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eight days (mean 20.73, SD 7.94) and Nys et al (2005) between two and 
fourteen days (mean 6.5, SD 2.9). Given that improvement is most rapid within 
the first three months following stroke (Hankey, 2002) this difference between 
testing time would potentially have a major impact on the impairments identified 
(and whilst Nys et al [2005] are critical of the Blake et al  [2002] study for 
delaying testing, there may be advantages in testing later in that it is possible 
that these impairments are less likely to be effected by spontaneous remission, 
and hence are more important to identify in terms of prognosis and planning 
long term care).      
 
A further difference between the Nys et al (2005), Cartoni and Lincoln (2005), 
and Blake et al (2002) studies that may have influenced their conclusions for 
cognitive impairment was the choice of tests used for the full battery 
neuropsychological testing. All three studies used extensive batteries, though 
Cartoni and Lincoln (2005) and Blake et al (2002) used a standard group of 
tests which were supplemented by alternative tests to further investigate any 
impairments identified: Nys et al (2005) used the same set of tests for each 
participant. Consequently, the Cartoni and Lincoln (2005) and Blake et al (2002) 
studies reported conclusions for cognitive impairment more akin to those in 
clinical practice whereas Nys et al (2005) reported more controlled results.  
 
A final difference between the three studies is that the Nys et al (2005) study 
recruited a matched control group from which to compare the conclusions of the 
testing, whereas the Cartoni and Lincoln (2005) and Blake et al (2002) studies 
both used published normative data from which to draw their conclusions. As 
with the discussion above on the use or otherwise of a standardised battery, the 
Nys et al (2005) study has an advantage in that it is better controlled whereas 
the other two studies better reflect actual clinical practice. 
 
It is interesting to note that whilst there is a wide variety in reported impairments 
(and bearing in mind that there is not a common pattern of impairment following 
stroke), language and communication difficulties have averaged as the least 
common impairment, yet receive substantial clinical input, at least when 
compared to that offered for other cognitive impairments (Royal College of 
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Physicians, 2008). This may be because communication and language is seen 
as a foundation to other work, because difficulty in communicating causes the 
patient significant distress or because rehabilitation and treatment processes 
are better defined and evaluated. Whatever the reason, there is potentially an 
argument that the remaining impairments are being somewhat under-
researched or unacknowledged given their prevalence. 
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1.6    Diagnostic Validity, Sensitivity and Specificity 
 
Diagnostic validity refers to a test’s ability to accurately predict the presence or 
otherwise of an impairment. It has been argued that diagnostic validity only has 
relevance if it also demonstrates utility, in that the diagnostic category that the 
test is attempting to identify should have been shown to be a discrete entity with 
natural boundaries that separate it from other similar syndromes (Kendell & 
Jablinsky, 2003). 
 
The diagnostic validity of a screening test can be ascertained by evaluation of 
its sensitivity and specificity. Sensitivity (the test’s ability to identify all people 
with an impairment) and specificity (the test’s ability to not include people 
without an impairment) can be measured by comparing the results of a test 
against those of other, well-established tests (tests with already established 
diagnostic validity). Therefore, if the number of people identified as being 
impaired by the screening test corresponds to the number identified as impaired 
by the established test, then the screening measure is highly sensitive. If they 
agree on those who are not impaired, then it is highly specific. In practice, there 
is a trade off between sensitivity and specificity, and acceptable rates are 
generally agreed to be 80% agreement or higher for sensitivity, and 60% or 
higher for specificity (Blake et al., 2002). 
 
An extension of sensitivity and specificity calculations involves calculating 
Positive Predictive Values (PPV) and Negative Predictive Values (NPV). PPV 
refers to the number of people who have been correctly diagnosed by a 
particular test, and NPV to the number who have been correctly identified as not 
having the diagnosis by the test. The higher the percentage of PPV and NPV, 
the better the diagnost accuracy of the test, with 50% indicating accuracy of no 
better than chance. Sensitivity, specificity, PPV and NPV are calculated by 
crosstabulation using the formula in table 5: 
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 TEST 1 (Gold Standard)  
 NCI CI Total 
NCI a  e 
CI  c f 
 
TEST 2 
Total b d  
Table 5: Calculation matrix for sensitivity and specificity, PPV and NPV. 
 
Specificity % can be calculated:  a/b x 100 
Sensitivity % can be calculated:  c/d x 100 
 PPV % can be calculated:          a/e x100 
NPV % can be calculated:           c/f x 100 
 
The cut-off score on a test that gives optimal sensitivity and specificity can be 
calculated using Receiver Operating Characteristic (ROC) curves. ROC 
analysis compares the sensitivity and specificity of a test at differing cut-off 
points which are plotted to produce a curve. A test that has excellent diagnostic 
validity will produce a curve that reaches the top left hand corner of the graph. 
This can be analysed more formally by calculating the Area Under the Curve 
(AUC), which is considered equivalent to the Mann-Whitney U and Wilcoxon 
rank tests (Spitalnic, 2004). The AUC score ranges between 0.5 to 1.0, with 1.0 
showing excellent diagnostic validity (sensitivity and specificity both 100%) and 
0.5 being very poor (no better than chance).  
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1.7     Evaluation of Screening Tests for Post Stroke Cognitive Impairment 
 
Though not part of the research procedure, the Sheffield Screening Test for 
Acquired Language Disorders (SST: Syder, Body, Parker & Boddy, 1993) was 
used to inform the inclusion / exclusion criteria regarding patients with aphasia. 
Whilst being a common and significant impairment following stroke (Hankey, 
2002) there are virtually no cognitive tests that control for the affect of aphasia 
on the testing process, and thus the inclusion of these patients would strongly 
bias the results (Srikanth et al, 2003). The authors of the SST reported good 
inter-relater reliability and provided normative data for various age groups 
based on a relatively small sample size of mainly older adults. The SST was the 
standard screening test for aphasia at the research hospital site, and was 
administered as part of the routine intake assessments, meaning that ethical 
approval was not required for its use as a screening test for inclusion/exclusion 
criteria, and consequently its use for this purpose did not add to the participants 
testing load. A cut-off score of <15 was used to standardise the inclusion / 
exclusion criteria with other comparable research papers (Blake et al, 2002). 
  
The MMSE was reported by Blake et al. (2002) to have good specificity (88%) 
and moderate sensitivity (62%) comparison for total score and overall 
conclusions for impairment following stroke (at a cut-off score of <24), but failed 
to find cut-off scores that would give adequate sensitivity or specificity in any 
specific cognitive domain. Nys et al. (2005) argued that the Blake study 
overestimated the sensitivity of the MMSE due to methodological problems 
(excessive differences in test intervals amongst participants). Their study 
concluded that a cut-off score of <24 only yielded sensitivity of 35% for 
cognitive impairment in acute stroke patients, and could not identify an optimal 
cut-off score. Further, the only cognitive domain that the MMSE showed any 
sensitivity to was verbal memory disorder (correctly identifying 4 out of 5 
patients), and, with a cut-off score of <24 failed to identify: 11 out of 16 (69%) of 
patients with reasoning disturbances (using the domain categories outlined 
above, this would be classed as executive dysfunction); 64% with executive 
disorders; and 57% with visual perceptual impairments. They concluded that 
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reliance on the MMSE could result in a majority of post-stroke cognitively 
impaired patients not receiving correct rehabilitation and in being discharged 
without the impairments being correctly identified. 
 
An evaluation of the Middlesex Elderly Assessment of Mental State (MEAMS; 
Golding, 1989 as cited in Cartoni & Lincoln, 2005) as a screen for post-stroke 
cognitive impairment reported only marginally better sensitivity than the MMSE. 
Cartoni and Lincoln (2005) reported good specificity (100%) but poor sensitivity 
(52%) comparison for total score and overall conclusions for impairment, using 
a cut-off of 3 or more fails. Sensitivity improved to 81% (with 50% specificity) 
when using 3 sub-tests to identify cognitive impairment in language, perception 
or memory. Sensitivity to executive functioning impairments was reported to be 
exceptionally poor at 11%.  
 
A description of some of the methodological differences between the Blake et al 
(2002), Nys et al (2005) and Cartoni and Lincoln (2005) papers is presented in 
Extended Paper 1.4 – Cognitive Impairment and Stroke, and so will not be 
repeated here. What is worth noting though is that the Nys et al (2005) study 
only reported the percentage of participants misclassified as cognitively non-
impaired, and Blake et al (2002) only reported the percentage figures for 
sensitivity and specificity: neither reported statistical significance or confidence 
intervals, and so it is difficult to draw conclusions from their results. Given the 
larger sample size of the Blake et al (2002) study, it is probable that greater 
statistical confidence can be given to these figures, though this would be 
conjecture and hard to estimate as they do not report their overall prevalence 
rate.  
 
Cartoni and Lincoln (2005) did report confidence intervals for their conclusions 
of impairment following stroke on the MEAMS. On their conclusions for the 
MEAMS at a cut-off of 3 or more fails, they reported sensitivity of 52% with a 
95% CI of 32-71%, and specificity of 100% with a 95% CI of 29-100%. On their 
conclusions for 5 or more fails, sensitivity was reported at 26% with a 95% CI of 
11-46%, and specificity of 100% with a 95% CI of 29-100%. Therefore, it can 
only be concluded with any confidence that the MEAMS was not a sensitive test 
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as the 95% confidence intervals did not reach 80%. However, the confidence in 
these results has to be tempered by the non reporting of the overall prevalence 
rate in this study (as it may be testing an unrepresentative sample).     
 
More recently, the Addenbrooke’s Cognitive Examination Revised (ACE-R; 
Mathuranath et al., 2000 as cited in Mioshi, Dawson, Mitchell, Arnold and 
Hodges, 2006) was proposed as an alternative to the MMSE as a potential 
screening tool for post-stroke cognitive impairment, after demonstrating good 
sensitivity (94%) and specificity (89%) for dementia (Mioshi et al., 2006). 
However, the results from a recent, and as yet unpublished, doctoral thesis, 
suggest that the ACE-R is a poor predictor of post-stroke cognitive impairment 
(sensitivity 77%, specificity 44%) (Lincoln, 2008), especially with regard to 
executive function and perception (N. Lincoln, personal communication, 15th 
December, 2008). 
 
A possible reason as to why these tests performed so poorly in identifying post 
stroke cognitive impairment could be due to the development of the tests to 
measure cognitive impairment in patients with dementia. Dementia literature 
often highlights memory impairments, as these are usually the earliest signs of 
a potential disorder (Morris & Kopelman, 1992). However, as discussed in 
above (Extended Paper 1.4 – Cognitive impairment and Stroke) executive 
dysfunction and visuospatial perceptual/attentional difficulties appear to be as, if 
not more, common following stroke. It could be possible that these tests would 
therefore be sensitive and specific for cognitive impairment with dementia, as 
impairments of executive dysfunction and visuospatial perceptual/attentional 
difficulties would be rather more rare and thus not show up in evaluation as a 
false negative (and if it were not fully measuring these impairments, as seems 
likely given the literature outlined above, would not show false positives). This 
appears to be supported by Srikanth et al (2006) who reported that a 
combination of the MMSE and the Informant Questionnaire for Cognitive 
Decline in the Elderly (IQCODE) failed to identify post stroke cognitive 
impairment, though were better at identifying post stroke dementia. 
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1.8    Detailed Description of RBANS 
 
The RBANS comprises of 12 sub-tests that are combined to form 5 index 
scores and a total score. The indexes (and sub-tests) are:  
Immediate Memory (List Learning, Story Memory) 
Visuospatial/Constructional (Figure Copy, Line Orientation);  
Language (Picture Naming, Semantic Fluency);  
Attention (Digit Span, Coding) 
 Delayed Memory (List Recall, List Recognition, Story Recall, Figure Recall). 
The RBANS does not have an index for executive function.  
 
Total score and index scores are reported as a standard score with a mean of 
100 and a standard deviation of 15, which are adjusted for age and education to 
allow comparison across groups. The test has a Form A and Form B, to allow 
for assessment of progression of impairment or to evaluate the outcome of 
clinical trials, which have good test – retest reliability (correlation coefficient of 
0.84 for people with schizophrenia, 0.77 for controls, Wilks et al., 2002), despite 
only a small proportion (N=100) of the original standardization sample receiving 
Form B, and good split-half reliability ranging from 0.80 to 0.94 (Randolf, 1998). 
 
 
The normative scores appear to be have been adequately validated, based on a 
sample of 540 individuals aged between 20 to 89 years, considered to be 
representative of the U.S. population using a census match (Randolf, 1998). 
Normative data for the individual test scores was not included in the test 
manual, but has been made available through Lezack, Howieson, & Loring 
(2004). A criticism of the normative data is that there is little range for younger 
normals in several sub-tests (picture naming, word list recognition, and figure 
copy) and thus a small effect on the sub-test can lead to a larger change in the 
index score (Randolf, 1998).  
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Several studies have provided supporting evidence for the use of the RBANS in 
screening for cognitive impairment in dementia.  Duff et al., (2008) reported that 
when cut-off scores of between one and one and a half standard deviations 
below the mean were applied, the RBANS demonstrated excellent diagnostic 
accuracy, especially with regard to Immediate and Delayed Memory index 
scores (area under ROC curve 0.96 and 0.98 respectively, where 1.00 is the 
highest possible), in patients with Alzheimer’s disease. However, as mentioned 
previously, evaluating a test for its validity against a dementia population does 
not mean that it is adequately testing for impairments of executive dysfunction 
and visuospatial/constructional difficulties. 
 
There is evidence that the RBANS has demonstrated good validity in screening 
for some cognitive impairments with heterogeneous groups as well as with 
differing specific populations. Gold, Queern, Ianhonem & Buchanan (1999) 
reported that the RBANS correlated well with several cognitive domains in a 
small sample of schizophrenic patients, but did not correlate with with language 
difficulties (though the study did not examine executive dysfunction and had a 
small sample size). In a follow-up study, Hobart, Goldberg, Bartko, and Gold 
(1999) compared the RBANS to full battery tests results from a larger sample 
(n=150) of diagnostically heterogeneous psychiatric outpatients. This paper 
concluded that the RBANS correlated well with some domains (notably attention 
and visual memory) but performed poorly at identifying executive difficulties. A 
minor criticism of this paper is that despite having a diagnostically 
heterogeneous group, the sample was limited to African Americans who were 
described as poorly educated and economically disadvantaged, and with high 
levels of substance co-morbidity; it would therefore be difficult to generalize 
these findings (though Patton et al, 2003, reported that differences between 
older African American and Caucasian subjects tests score were similar in 
difference on the RBANS as with other psychometric tests) . A more pertinent 
criticism would be that the full battery testing was somewhat limited in scope, 
and that there was only one measure for executive function, Wisconsin Card 
Sorting Test, which may have disadvantaged any participants with visuospatial 
impairment. Equally, there are several sub-domains of executive functioning, 
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and it cannot be concluded that a failure to correlate to one means that the 
RBANS does not identify executive dysfunction. 
 
Several other studies that have provided supportive evidence for the use of 
RBANS as a screening test for cognitive impairment, though these have tended 
to focus on assessing the RBANS as a measure of overall cognitive impairment, 
rather than using it to identify impairment in particular domains. The populations 
for which the RBANS has been evaluated include; psychotic adolescents 
(Holtzer et al., 2007); multiple sclerosis (Beatty, 2004); traumatic brain injury 
(McKay, Wertheimer, Fichtenberg, and Casey, 2008); and end-stage liver 
disease (Sorrell, Zolnikov, Sharma, and Jinnai, 2006). Additionally, there is 
some supportive evidence for the ecological validity of the RBANS, with 
Terryberry-Spohr, Gordon, & List Kalins (2000) concluding that the RBANS 
predicted functional outcome (as measured by the Functional Independence 
Measure (FIM)) equally as well as lengthier neuropsychological batteries 
(though of course this does not mean that neuropsychological tests predict 
functional outcome) in a heterogeneous sample of 118 psychiatric in-patients. 
This finding was supported by Bennett (2006) who concluded that the RBANS 
total score, and especially the index scores of Attention, Immediate Memory, 
and Visuospatial abilities, predicted functional abilities in dementia patients. 
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1.9 Studies Relating to RBANS and Stroke 
 
Support for the ecological validity of the RBANS index scores in stroke patients 
has been reported by Larson et al (2003). In a 6-month follow-up study of 34 
inpatient stroke patients, they found that: multiple regression of initial 
visuospatial/constructional, delayed memory, and attention indexes predicted 
46% of the variance of the cognitive measure of the FIM at follow-up (with 
delayed memory also making a significant individual prediction (r=0.61, 
p<0.002)); the same three indexes predicted 22% of the Motor (measuring 
functional activities) FIM variance (visuospatial/constructional index correlated 
r=0.46, p<0.01); 14% of frequency of activity (visuospatial/constructional r=0.46, 
p<0.01); 17% of life satisfaction (language r=-0.47, p<0.01); and 21% of 
physical disability (visuospatial/constructional r=0.46, p<0.01). 
 
These findings are consistent with those reported by Terryberry-Spohr et al 
(2000) mentioned above, and those of Hoye et al (2000) in a study of stroke 
patients undergoing inpatient rehabilitation, which also suggested that the 
RBANS could differentiate the hemispheric side of the stroke. Combined, these 
studies would indicate that the RBANS demonstrates reasonable ecological 
validity for stroke patients, and is especially strong at predicting cognitive 
impairment. A limitation of the Larson (2003) study, that only a small proportion 
of patients could be contacted for follow-up, is probably compensated for by the 
reliability of these findings across the three studies. 
 
In a carefully controlled study of a large sample of in-patient stroke patients, 
Wilde (2006) found intercorrelations between RBANS index scores similar to 
those reported by Randolf (1998), but factor analysis did not support the 5 
indexes purporting to measure the cognitive domains. Instead, the results 
suggested a 2 factor solution of visuospatial/visual memory and 
language/verbal memory factors. The latter of these factors strongly correlated 
with an independent measure of language and executive function (r=0.65, 
p<0.001) as did the former at a slightly weaker level (r=0.30, p=0.04). Measures 
of neglect and visuospatial impairment were also significantly correlated, though 
no correlation was found between the RBANS and measures of receptive 
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language. It is interesting to note therefore that the RBANS is a potentially valid 
measure of executive dysfunction in stroke patients, despite not having this as 
an index score.    
 
Finally, Duff, Beglinger, Kettmann, & Bayless (2006) reported a single case 
study of a 22 year old psychiatric patient who suffered a stroke following 
screening with the RBANS. This paper suggested that the RBANS 
demonstrated sensitivity to pre and post stroke cognitive impairment variations 
(despite the patient having pre-existing cognitive impairments), and being 
especially sensitive on the visuospatial/constructional index. The RBANS also 
demonstrated stability on sub-tests where cognitive impairment was not 
identified by full battery testing. Whilst not generalisable to the larger stroke 
population, and many potentially confounding variables could not be controlled, 
this paper appears to add support to some of the findings detailed above. 
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1.10    Research Aims 
 
A further additional aim of this research project initially was to compare the 
RBANS conclusions for sensitivity and specificity with those of the MMSE, to 
ascertain which had the better diagnostic validity. This was an original aim due 
to the common usage of the MMSE as a global screening test for cognitive 
impairment (Nys et al, 2005) and its continued use specifically as a screening 
test for post stroke cognitive impairment. Several studies (e.g. Nys et al, 2005, 
Cartoni & Lincoln, 2005) have concluded that the use of the MMSE for this task 
is not appropriate.  
 
Ethical approval was not sought to administer the MMSE for this study as it was 
already in use as a routine screening test on the stroke wards identified (ethical 
approval was sought to gather this data from the medical notes). However, by 
the time that this study had been granted ethical approval, the stroke wards had 
begun to replace the use of the MMSE with the Montreal Cognitive Assessment 
(MoCA:  Nasreddine, 2004). Consequently there was little data that could be 
collected on the MMSE, and by the time the study came to be written up, not 
enough had been collected to be appropriately included in the study. Approval 
was not sought to administer the MMSE separately, firstly because the testing 
load on participants of the study was already high (and thus it did not seem 
appropriate to add the MMSE to either the RBANS or full battery testing) and 
secondly, administering the MMSE separately to the other testing would have 
involved identifying a further research assistant, and this did not appear to be 
likely to happen.  
 
A final aim of the study was to establish whether an extended study into the 
sensitivity and specificity of the RBANS as a screening test for post stroke 
cognitive impairment was justified and feasible. The justification for an extended 
study would be centred on the results of this pilot in terms of whether 
acceptable levels of sensitivity and specificity could be reasonably predicted, 
based on a sample size comparable to previously published research (e.g. 
Cartoni & Lincoln, 2005, Nys et al, 2005). The feasibility of an extended study 
was concerned with prevalence rates identified within the pilot for global and 
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domain specific cognitive impairments, and the implication of these on 
estimated sample size. The pilot would also provide information as to expected 
recruitment rates, estimated staff time, time scales, and in identifying any 
unforeseen obstacle. Equally, the pilot would provide an opportunity to evaluate 
the utility of the neuropsychological test battery.  
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2.     EXTENDED METHODS 
 
2.1    Sample Size 
 
The initial sample size for this study was arrived at based on research 
experience, clinical expertise and previous studies using the same design to 
report sensitivity and specificity of post stroke cognitive impairment screening 
tests. This suggested that in order to be meaningful the sample should be large 
enough to ensure that there is a minimum of 10 participants in each condition 
(cognitively impaired and non-cognitively impaired) (N. Lincoln, personal 
communication, 16th January, 2009). According to a study by Nys et al. (2005), 
“70% of stroke patients were impaired in at least 1 cognitive domain”  (p627). 
Therefore, in order to ensure 10 participants in the non-cognitively impaired 
category, a minimum of 30 participants were required (i.e. 30 participants x 
30%[non-impaired] = 10 participants in the non-cognitively impaired category). 
This number was comparable with other similar studies (e.g. Cartoni & Lincoln, 
2005, Nys et al, 2005). Due to the nature of acute stroke wards, where patients 
are often moved at short notice (for instance discharged from care or as a result 
of complications), a relatively high drop out rate was expected for this study (for 
instance, Cartoni & Lincoln, 2005, had 7 out of 37 participants drop out), which 
suggested that 40 patients should be recruited as participants to arrive at a 
sample size of 30. 
 
This sample size was challenged during the ethical approval process. Buderer 
(1996) reported that studies evaluating the diagnostic validity of a test frequently 
overlooked the importance of statistical issues in estimating the required sample 
size, relying instead on factors such as previous research sample sizes, cost, 
past experience and convenience. Whilst acknowledging that these are 
important factors, Burderer (1996) also argued that too small a sample size 
could result in imprecise estimates of sensitivity and specificity, as well as 
potentially resulting in misleading results if the sample does not reflect the 
prevalence of the disorder in the target population. Burderer (1996) provided 
statistical methods to calculate an acceptable sample size based on the 
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“clinically acceptable degree of precision, the hypothesised value of sensitivity 
and specificity and estimated prevalence of the disease” (p895).    
 
Estimates of prevalence rates of global and domain specific post stroke 
cognitive impairment vary (see table 3), and this has implications in calculating 
the sample size for a study of this type. Equally, the cutting points of >80 and 
>60 for adequate sensitivity and specificity respectively are well established; 
what is unknown are the expected sensitivity and specificity rates of the 
RBANS. However, an educated estimation of these rates are needed to 
complete a sample size calculation, and a present these are unknown. The 
current pilot study was planned with a sample of 40 participants which would be 
comparable to previously published research paper as described above, and 
would allow an estimate of the prevalence rates of global and domain specific 
cognitive impairment to be identified, as well as providing information regarding 
the expected sensitivity and specificity rates, and would thus provide 
information that could be used to calculate a sample size that would provide 
results within an acceptable confidence interval. This information would then be 
used to inform an extended study if the pilot results suggested that this was 
justified and feasible. The Burderer (1996)  calculation for sample size 
estimation is detailed as:  
 
Specifications: 
Specify the maximum clinically acceptable width of the 
95% CI. Call it W. 
Specify an estimate for the prevalence of disease in the 
target population. Call it P. 
Specify a value for the expected sensitivity of the new 
diagnostic test. Call it SN. 
Specify a value for the expected specificity of the new 
diagnostic test. Call it SP. 
(For purposes of calculations, W, P, SN, and SP are expressed 
as numbers between 0 and 1, rather than as percentages.) 
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Calculate the Number with Disease, TP + FN: 
 
 
Calculate the Sample Size Required for Sensitivity, N1: 
 
N1 = TP+FN 
              P 
 
       
 
Calculate the Number without Disease, FP +TN: 
 
 
 
Calculate the Sample Size Required for Specificity, N2: 
 
N2 = FP+TN 
          (1 – P) 
 
       
 
The estimated sample size is whichever is the greater of N1 or N2 
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2.2     Consent 
 
Capacity to give informed consent to participate in the study was ascertained in 
two ways. Firstly through consultation with the healthcare team, including 
reference to the routine intake assessments, and secondly, after discussing 
possible participation with a member of the research team, the research team 
member asking the potential participant to repeat back their understanding of 
what participation in the study would involve. If the potential participant was 
unable to demonstrate an understanding of the process of involvement in the 
study then they were not recruited for the study. If capacity to give informed 
consent was evident, then the potential participant was asked to participate, and 
if they agreed to do so, signed a consent form. 
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2.3 Test Cut-Off Points 
 
Cognitive impairment for conclusions of cognitive impairment on the 
neuropsychological test battery was defined as scoring below the 5th percentile 
for age-adjusted norms on each of the battery tests. In clinical practice such a 
cut-off score would be arbitrary and a decision about the presence of a 
cognitive impairment or otherwise would be taken with reference to the wider 
clinical picture. To some extent the cut off score on a diagnostic validity study, 
where the boundaries are blurred between impairment and non impairment, is 
also arbitrary, as what is being examined is the extent to which a score on one 
test agrees with the score on another. A score with a specified SD below the 
pre-morbid estimate could have been used, though accurately defining the pre-
morbid estimate can be problematic, and this still leaves the problem of how 
many points below the SD to chose, as 1SD may result in false positive results, 
and 2 SD in false negatives (Lezak et al, 2004). The decision to use below the 
5th percentile was based on clinical and research experience (N. Lincoln, 
personal communication, 16th January, 2009), and on convention the that a cut-
off score, in the absence of other methods of differentiating impairment from 
non impairment, can be expected to be reasonably accurate if it  compares to 
the lowest score made by 95% of the normative sample (Lezak et al, 2004). 
This also has the advantage of not being based on individual differences, 
instead expecting an overall reduction to the mean, as well as making 
comparison with similar studies easier.  
 
The cut-off score for identifying cognitive impairment on the RBANS was taken 
from the RBANS manual (Randolph, 1998) as being 69 or below on the Total 
Scale and Index scores. This cut-off represents the lowest 2% of scores from 
the normative data. In a study of cognitive impairment in people with dementia, 
Duff et al (2008) reported excellent diagnostic validity for the RBANS when cut-
off point of between 1 and 1 ½ SD below the mean were used. This was applied 
to the RBANS cut-off points for subtest scores in this study as standard scores 
are not available for these. 
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Cut-off scores are a major feature of screening tests and intrinsic to the 
evaluation of the diagnostic validity of a test. However, Cullen, O’Niell, Evans, 
Coen and Lawlor (2007) point out that a reliance on a single piece of data runs 
counter to most clinicians approach to diagnoses, which is based on the testing 
of various hypotheses, taking into account various factors including qualitative 
information not provided by a single score. Whilst this is a very valid comment, it 
is less applicable to this study, as the research being undertaken here does not 
in any way suggest that screening for post stroke cognitive impairment should 
replace or substitute professional neuropsychological investigation, more that it 
can aid in directing these investigations towards those most likely in need of 
them.   
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2.4     Neuropsychological Test Battery 
 
The battery tests were selected to identify global cognitive impairment and a 
broad range of investigation, as well impairment within the specific cognitive 
domains of interest in the study. A test battery created in this way has the 
advantage of meeting the criteria required for this study, though has the 
disadvantage of not being subjected to a large scale standardisation study 
(Lezak et al, 2004). However, the tests were chosen due to their good levels of 
reported reliability and validity (including standardisation and normative data), 
their common usage in neuropsychological testing, and the relative brevity of 
their administration (thus not subjecting the participants to unnecessarily 
lengthy testing).  
 
For Immediate and Delayed Memory the Rey Complex Figure (Meyers & 
Meyers, 1995) and selected sub-tests of the Wechsler Memory Scale third 
edition (WMS III: Wechsler, 1997a) were chosen. The Rey Complex Figure is a 
well established and widely used test with good psychometric properties, and 
has demonstrated good sensitivity to even mild cognitive impairment across a 
wide range of disorders (Lezak et al, 2004). The WMS III memory test battery is 
widely used and well established, with good overall reliability, though several of 
the individual sub-tests have limited reliability and validity, especially Faces I 
and II (Lezak et al, 2004). However, the Logical Memory sub-tests have 
demonstrated good reliability when compared to other similar tests and appear 
to demonstrate ecological validity (Lezak et al, 2004). 
 
The WMS III sub-tests of Digit Span and Letter/Number Sequencing were 
selected to assess Attention, again due to the WMS III reporting relatively good 
levels of reliability and validity (Wechsler, 1997a). These sub-tests are also 
included in the WAIS III battery (Wechsler, 1997b) and as such have been 
exposed to further extensive evaluation. 
 
As well as being included for Immediate and Delayed Memory, the Rey 
Complex Figure is initially copied to assess for Visuospatial impairment. 
Visuospatial impairment was also assessed by the Behavioural Inattention Test 
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(BIT) Star Cancellation (Wilson, Cockburn & Halligan, 1987) sub-test which has 
demonstrated good correlation with other tests of visual inattention as well as 
showing good sensitivity to impairment within various disorders (Lezak et al, 
2004). The Visual Object and Space Perception Test (VOSP: Warrington & 
James, 1991) was also administered as part of the test battery to assess for 
Visuospatial impairment, again due to its extensive use and generally well 
reported psychometric properties (Lezak et al, 2004), though reliability of the 
Position Discrimination sub-test was reported as poor by Bonello, Rapport & 
Millis (1997). 
 
The short NART (Beardsall & Brayne, 1990) was used to assess pre-morbid 
intelligence. The NART itself has well established psychometric properties 
(Lezak et al, 2004). Beardsall & Brayne (1990) reported that the predictions of 
the short NART were very highly correlated with the full NART scores, thus 
providing a shorter, and consequently less taxing, test of pre-morbid intelligence 
estimate.  
 
Executive Functioning was assessed by the Modified Card Sorting Test (MCST: 
Nelson, 1976) and Brixton Spatial Anticipation sub-test of the Hayling and 
Brixton test (Burgess & Shallice, 1997). The MCST is a modified version of the 
Wisconsin Card Sorting Test, a test that had been shown to be reliable in 
identifying brain lesions in people with suspected brain damage (Milner, 1963, 
as cited in Nelson, 1976). The MCST uses half the number of cards as the 
WCST and has slightly different administration rules, making it easier for 
testees to tolerate (and with reference to this study, completing the full WCST 
would have added to great a testing burden to the full battery, both in terms of 
duration and potential for fatigue). Nelson (1976) reported the MCST to be a 
good predictor of frontal lobe lesions, and the test has subsequently 
demonstrated good levels of reliability and validity (Lezak et al, 2004). The 
Brixton Spatial Anticipation Test also demonstrated reliability in discriminating 
frontal lobe lesions (Burgess & Shallice, 1997) though has been criticised for 
placing a heavy demand on working memory (Lezak et al, 2004). 
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Executive function was also assessed by the Controlled Word Association Test 
(COWAT: Benton & Hamsher, 1989) FAS test. The COWAT: FAS is a well 
established test of language impairment and one of the few tests of verbal 
fluency to have extensive normative data (Tombaugh, Kozak & Rees, 1999). 
The FAS has also been shown to be particularly sensitive to severity and 
location of stroke (Spreen & Benton, 1977).  The COWAT: FAS was chosen for 
inclusion in the full test battery to provide an alternative measure of executive 
function impairment for those participants with visual neglect who would not be 
able to reliably complete the Brixton test and MCST.   
 
There are a myriad of alternative tests that could have been chosen for the test 
battery in place of those selected, and the ones listed have been influenced by 
factors such as availability and clinical preference/experience as well as for the 
more formal reasons outlined above. Alternative tests that were considered 
included the more recent WMS (WMS IV: Wechsler, 2010), though this was not 
included firstly due to the pragmatic consideration of cost, and secondly due to 
the fact that it does not contain the Logical Memory sub-tests and would have 
potentially necessitated the completion of the full test (thus lengthening the 
testing process). The WMS IV does however claim enhanced clinical utility as 
well as extended normative data (Wechsler, 2010). The Rey Auditory Verbal 
Learning Test has demonstrated good psychometric properties (Strauss, 
Sherman & Spreen, 2006) and was considered as a measure of immediate and 
delayed memory, though the test appears to lack the ecological validity of the 
WMS III Logical Memory tests, as well as requiring a relatively high functioning 
level to complete. The Trail Making Test (TMT) is frequently included in 
neuropsychological tests batteries and has been shown to be sensitive to a 
wide range of cognitive impairments (Reitan & Wolfson, 1985). However, whilst 
the TMT is a good indicator of global cognitive impairment, there is debate as to 
which particular domains it measures (Lezak et al, 2004), and this would have 
made its inclusion in the test battery for this study problematic in terms of 
comparing it to the specific components of the RBANS being investigated. 
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2.5     Details of Research Procedure 
 
If patients were considered as suitable for inclusion in the study, they were 
initially approached by a member of healthcare team to participate and 
introduced to a member of the research team (either the chief investigator or the 
research assistant) and given the patient information sheet. The potential 
participant was encouraged to discuss potential participation with family, carers, 
healthcare staff and researchers. The researcher then recorded on a record 
sheet that the Participant Information sheet had been given. Potential 
participants were informed that they were under no obligation to participate, and 
that not participating would in no way affect the care provided. The patient was 
then approached by a member of the research team after having had a 
minimum of 48 hours to decide. If the patient had decided to participate, the 
information sheet was discussed, any questions answered, the patients 
understanding of the study ascertained, and informed consent taken by signing 
the consent form. If capacity to give informed consent could not be ascertained, 
the patient was informed that their involvement would be discussed with the 
healthcare team to decide whether it would be in their best interest to 
participate. 
 
After giving informed consent the participant then completed either the RBANS 
(with the research assistant) or the full battery tests (with the chief investigator). 
Alternating between initial administration of the two sets of tests was achieved 
through reference to the record sheet, with either the RBANS of full battery 
testing being allocated on an opportunity basis. The Chief Investigator and 
assistant psychologist regularly reviewed the record sheet to see who had been 
given the Participant Information Sheet and who were thus waiting to be 
approached regarding participation, as well as to review who had completed the 
initial set of tests. Whilst the participants had been informed that the second 
testing would take place within a maximum of 2 weeks, in practice it generally 
occurred within the same week. The participant was then administered the 
alternate set of tests i.e. the full battery, administered by the chief investigator, 
or the RBANS, administered by the research assistant.  
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The RBANS and full battery tests were administered according to the individual 
manual instructions. The initial testing was scored and the record sheet 
completed listing the Participant ID number, the date consent was taken, and 
the date of completion of the first testing. The ID number was allocated in order 
that consent was taken. The consent form was then filed in the healthcare notes 
and the completed tests in a box file locked in a secured filling cabinet on the 
ward. The alternative test was recorded and filed using the same process. The 
organization and day-to-day management of the study (including liaising with 
the ward staff teams) was the responsibility of the Chief Investigator. The 
research procedure is summarised below in Figure 1. 
 
Patient admitted to ward 
 
Patient administered intake assessments, including SST and MMSE or MoCA , 
and assessed for exclusion criteria 
(by member of healthcare and research team) 
 
Patient approached for further study participation, given information sheet, and 
48 hours to decide (by member of healthcare and research team) 
 
Participant informed consent obtained 
(by member of research team) 
 
RBANS (research assistant) or Full Battery  (chief investigator) completed 
 
Participant asked if there has been a change in their medical condition, and if 
not alternative tests completed (RBANS or Full Battery) 
(by research assistant/chief investigator) 
 
Data coded, inputted and analysed by Chief Investigator 
Figure 1. Flowchart of the research procedure 
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2.6    Ethical Approval 
 
The main ethical considerations identified before submission for ethical 
approval were assessing capacity to give informed consent, the estimation of an 
adequate sample size (to allow for generalisability of the results, and thus not 
subjecting participants to extensive testing without generating useable data) 
and the possible detrimental effect of lengthy neuropsychological testing on 
unwell participants.  
 
Capacity to give informed consent was guided by good clinical practice 
guidelines and relevant local trust policies and procedures, and took into 
account the need for this to be informed at an MDT level. The sample size was 
determined by estimates of the prevalence of cognitive impairment in the 
proposed population, and based on previously published research. The 
detrimental effects of lengthy neuropsychological testing were addressed by 
choosing appropriate tests that were relatively quick to administer, as well as 
ensuring that the participants were aware beforehand of the duration of the 
testing and allowing breaks when needed. A further ethical consideration 
concerned whether to reveal the results of the testing to the participants, as this 
could be seen as an inducement to participate or detrimental to non-
participants. However, after discussion with the Research Ethics Committee 
(REC) it was decided that the test results should be made available to 
participants and their carers (with the participants consent). Other ethical issues 
included maintaining participant confidentiality and data storage. Participant 
confidentiality was achieved by the use of anonymised study ID numbers, and 
data storage concerns were addressed by ensuring that all the test score 
sheets were kept in a secured file on the ward for the duration of the study. 
Information that was taken off the ward for the purpose of this study (namely the 
test result scores and basic demographic information) were kept electronically 
on a password encrypted memory stick, and were backed up on the password-
protected network on the University of Lincoln computer system. After the 
completion of the study the test sheets were securely stored at the University of 
Lincoln, and will be securely destroyed after 7 years. 
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The Research Ethics Committee highlighted several further issues as ethical 
concerns. The most pertinent of these were restricting the age of participants to 
those covered by the normative data samples identified in the published 
manuals for the full battery neuropsychological tests, and the need for a formal 
sample size calculation to be performed. Ethical approval was sought to 
complete the study across two sites to allow for access to a larger number of 
potential participants and the REC requested that both sites followed the same 
methodological procedure. However, a research assistant could not be 
identified to complete the RBANS testing at one of the sites meaning that the 
study could not be conducted there (as the chief investigator could not 
administer both the full battery and RBANS as he had to be blind to one set of 
tests to control against researcher bias). All requests for amendments to the 
study were complied with, and the details of these (and the other issues 
highlighted by the REC) are provided in Appendix B. The impact of these 
amendments on the study are discussed in Extended Paper 4.2. 
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3.    EXTENDED RESULTS 
 
3.1 Normality of Distribution 
 
Analysis of the demographic variables of the recruited sample was performed to 
test for normality of distribution. As the sample size was less than 50 (n=40 
<50), the Shapiro-Wilks test was used, where p>0.05 indicates normal 
distribution. Analysis showed that Age, Gender and Years of Education were 
not normally distributed (Age: W(40) = 0.81, p<0.001, Gender: W(40) = 0.62, 
p<0.001, Years of Education: W(40) = 0.78, p<0.001). The Interval Between 
Testing was not normally distributed (W(40) = 0.71, p<0.001), and neither was 
time from admission to final testing  (W(40) = 0.87, p<0.005). The RBANS Total 
Scale score was normally distributed (W(40) = 0.96, p>0.1), as were the 
RBANS Immediate Memory scale (W(40) = 0.95, p>0.05), the Attention scale 
(W(40) = 0.97, p>0.4) and the Delayed Memory scale (W(40) = 0.96, p>0.1). 
The RBANS Visuospatial/Constructional and Language scales were not 
normally distributed (W(40) = 0.92, p<0.01, and W(40) = 0.90, p<0.005 
respectively).  
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3.2 Demographic Details 
 
No demographic details were recorded for patients who did not consent to 
participate. Consequently no analysis could be done to explore demographic 
differences between participants and non-participants. 
 
Analysis of the relationship between the RBANS Total Scale score and 
demographic information showed that there was no statistically significant 
relationship between RBANS Total Scale score and Age (r(40) = -0.29, p>0.05) 
or gender (t(40) = 1-13, p>0.1), though there was a statistically significant 
relationship between the Total Scale score and years of education: r(40) = 0.63, 
p<0.001.  
 
Analysis of difference between participants identified as cognitively impaired 
and non-impaired by the full battery of neuropsychological tests showed that 
there was no statistically significant difference identified by age: U = 74, p>0.1, 
and that there was a statistically significant difference according to years of 
education: U = 30, p<0.001. Analysis also showed that gender was a 
statistically significant predictor of classification of impairment: Chi-square =  
5.09, p>0.05, with no females identified within the non-cognitively impaired 
category. 
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3.3 Descriptive Details 
 
Details of the mean scores on the RBANS indexes and individual full battery 
tests, together with conclusions for cognitive impairment, are presented below 
in table 6. The conclusions for RBANS cognitive impairment are based on the 
manual suggested cut-off score of 69, with the conclusions for the individual 
tests comprising the full battery being based on the 5th percentile cut-off point 
(unless using the manual based cut-off point for tests such as the VOSP, as 
detailed previously), Note that not all participants completed every test on the 
full battery. This was due to several factors: firstly, if a participant was unable to 
complete a test due to an impairment identified in a separate cognitive domain 
(e.g. visual neglect making completion of the MCST invalid) and secondly, if a 
score on an earlier administered test indicated impairment in that domain thus 
making continued testing of that domain redundant and unnecessarily adding to 
the participant’s testing load.   
 
Table 6. Descriptive details from the RBANS and full battery testing. 
Assessment 
 
 
n Mean SD Range n impaired 
(%) 
RBANS 
     
Immediate Memory 40 81.87 23.13 40 – 123 14 (35%) 
Visuospatial/construction 40 77.32 24.97 40 – 131 20 (50%) 
Language 40 85.70 17.67 40 – 117 6 (15%) 
Attention 40 77.75 18.54 46 – 128 16 (40%) 
Delayed Memory 40 77.47 22.72 40 – 119 16 (40%) 
Total Scale 40 75.73 20.48 44 – 121 17 (43%) 
      
Full Battery 
     
Logical Memory I 40 28.08 12.89 3-47 10 (25%) 
Rey Copy 34 11.26 13.53 0 – 34 20(59%) 
Digit Span 40 14 4.88 7 – 27 6 (15%) 
Rey Immediate Recall 31 4.93 8.21 0 – 29 17 (54%) 
Letter Number Sequencing 37 5.43 4.00 0 – 15 20 (54%) 
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BIT Start Cancellation 38 45.44 9.80 17 – 54 18 (47%) 
VOSP Incomplete Letters 37 15.15 5.01 7 – 20 18 (49%) 
VOSP Dot Counting 39 7.86 2.91 0 – 10 18 (46%) 
VOSP Position Discriminatin 26 17.36 3.51 7 – 20 9 (34%) 
COWAT: FAS 40 25.44 14.09 2 – 68 12 (30%) 
Logical Memory II 40 13.33 9.25 0 – 27 14 (35%) 
Rey Delayed 28 8.25 9.51 0 – 27 15 (54%) 
MCST 22 7.08 6.41 1 – 22 10 (45%) 
Brixton Spatial Anticipation 
Test (Errors) 
27 24.68 9.34 2 – 31 18(69%) 
Overall conclusions 40    33 (82.5%) 
 
 
Further analysis indicated that the scores on the RBANS total scale were not 
related to type of stroke (i.e. TACS, PACS, POCS, or Lacunar): F = 1.25, p>0.3, 
or hemisphere of stroke: t = --0.10, p>0.9. Analysis also showed that there was 
no statistically significant correlation between RBANS Total Scale scores and 
days from admission: r=0.13, p>0.4, or the interval between testing on the 
RBANS and full battery: r = -0.18, p>0.2. Cause of stroke (i.e. haemorrhage or 
ischemia) did demonstrate a statistically significant difference on the RBANS 
Total scale (t=-2.6, p<0.05) though the small number of haemorrhage 
classifications (n=4) would invalidate this analysis (95%CI = -46.4 to –5.8). 
 
Type of stroke was not a statistically significant predictor of classification of 
impaired / non-impaired on the full battery testing (Chi-square = 6.88, p>0.05), 
neither was hemisphere of stroke (Chi-square = 0.48, p>0.7). Neither days from 
admission nor the interval between testing showed a statistically significant 
relationship with classification by the full battery testing (days from admission: U 
= 93, p>0.5, and interval between testing: U = 77.5, p>0.5). 
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3.4 Diagnostic Validity Using Recommended Cut-Off Scores 
 
Table 7 shows the sensitivity, specificity, PPV and NPV (with 95% confidence 
intervals) for RBANS global and domain specific conclusions for impairment 
following stroke, based on the manual recommended cut-off of <69 (Randolph, 
1998) when compared to the full battery conclusions, with adequate levels 
being highlighted. Using the recommended cut-off score, the RBANS Total 
Scale showed 100% specificity to global cognitive impairment (95% CI = 56-
100) but poor sensitivity (52%, 95% CI = 34-69). Identification of impairment on 
1 or more Indexes showed adequate levels of both sensitivity and specificity 
(82%, 95% CI = 63-92, and 100%, 95% CI = 56-100) for detecting global 
cognitive impairment after stroke. 
 
None of the domain specific indexes demonstrated adequate sensitivity, though 
all demonstrated acceptable levels of specificity (Immediate Memory = 79%, 
95%CI = 60-91, Visuospacial = 94%, 95% CI = 68-99, Attention = 79%, 95% CI 
= 54-93, and Delayed Memory = 81%, 95% CI = 57-94).  PPV ranged from 57-
100%, with Total Scale (100%, 95% CI = 77-100), Impairment Identified on 1 or 
more Indexes (100%, 95% CI = 84-100), and Visuospatial (95%, 95% CI = 73-
100) showing good accuracy for positive results. Good accuracy for negative 
results was only shown by the Immediate Memory scale (NPV = 88%, 95%CI = 
69-97). 
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Table 7. Sensitivity, specificity, positive and negative predictive values for 
RBANS conclusions based on recommended cut-off scores 
RBANS Index 
(Subtest) 
Sensitivity 
(95% CI) 
Specificity 
(95% CI) 
Positive 
Predictive Value 
(95% CI) 
Negative 
Predictive 
Value (95% 
CI)  
Total Scale 52%  
(34-69) 
100%  
(56–100) 
100%  
(77-100) 
30%  
(14-53) 
Impairment 
on 1 or more 
Indexes 
82% 
(63-92) 
100% 
(56-100) 
100% 
(84-100) 
54% 
(26-80) 
Immediate 
Memory 
73% 
(39-93) 
79%  
(60-91) 
57%  
(30-81) 
88%  
(69-97) 
Visuospatial 79%  
(57-92) 
94% 
(68-99) 
95% 
(73-100) 
75% 
(51-90) 
Attention 57% 
(33-77) 
79% 
(54-93) 
75% 
(47-91) 
63% 
(40-80) 
Delayed 
Memory 
63% 
(39-83) 
81% 
(57-94) 
75% 
(47-92) 
71% 
(49-87) 
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3.5     Cross Tabulations 
 
Table 8 shows the cross tabulations for RBANS scores and full battery 
conclusions for Cognitive Impairment (CI) and Cognitive Non-Impairment (NCI) 
using RBANS recommended cut off point of 69 to identify CI. For the RBANS 
Total Scale and Index Conclusions (i.e. categorisation of CI on at least one of 
the indexes), the full battery conclusions are based on categorisation of CI/NCI 
in any single domain; for the RBANS domain specific conclusions, the full 
battery conclusions are based on categorisation of CI/NCI on the corresponding 
cognitive domain.   
 
Table 8.  RBANS Total and Index scales cut off score < 69 and Full Battery 
overall conclusions 
  Full Battery  
NCI 
Conclusions 
CI 
 
Totals 
     
RBANS Total CI 0 17 17 
Scale NCI 
Totals            
7 
7 
16 
33 
23 
40 
     
RBANS Index CI 0 27 27 
Conclusions NCI 7 6 13 
 Totals 7 33 40 
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Immediate CI 6 8 14 
Memory NCI 23 3 26 
 Totals 29 11 40 
     
Visuospatial CI 1 19 20 
 NCI 15 5 20 
 Totals 16 24 40 
     
Attention CI 4 12 16 
 NCI 15 9 24 
 Totals 19 21 40 
 
 
    
Delayed CI 4 12 16 
Memory NCI 17 7 24 
 Totals 21 19 40 
 
 
Table 9 shows the cross tabulations for RBANS scores and full battery 
conclusions for Cognitive Impairment (CI) and Cognitive Non-Impairment (NCI) 
using RBANS optimum cut off points as identified by ROC analysis. 
 
Table 9.  RBANS Total Scale and Index scores (with ROC analysis identified 
optimum cut off scores) and Full Battery overall conclusions 
  Full Battery  
NCI 
Conclusions 
CI 
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Totals 
     
RBANS Total CI 2 33 35 
Scale (102.5) NCI 
Totals 
5 
7 
0 
33 
5 
40 
     
Immediate CI 8 9 17 
Memory (79.5) NCI 21 2 23 
 Totals 29 11 40 
     
Visuospacial (88) CI 4 24 28 
 NCI 12 0 12 
 Totals 16 24 40 
     
Attention (86.5) CI 10 18 28 
 NCI 9 3 12 
 Totals 19 21 40 
 
 
    
Delayed CI 8 18 26 
Memory (90.5) NCI 13 1 14 
 Totals 21 19 40 
 
 
Tables 10 shows the cross tabulations for RBANS total and index scores and 
full battery conclusions for Cognitive Impairment (CI) and Cognitive Non-
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Impairment (NCI) on Executive Function tests, using RBANS recommended cut 
off points of 69. (N.B. that the Language scale was artificially affected by 
language impairment being a study exclusion criterion). 
 
 
 
 
Table 10. RBANS Total scale and index scores and full battery conclusions for 
executive functioning impairment 
 
  Full Battery  
NCI 
Conclusions 
CI 
 
Totals 
     
RBANS Total CI 1 16 17 
Scale NCI 
Totals 
15 
16 
8 
24 
23 
40 
     
Immediate CI 1 13 14 
Memory NCI 15 11 26 
 Totals 16 24 40 
 
Language 
 
CI 
NCI 
Totals 
 
0 
16 
16 
 
6 
18 
24 
 
6 
34 
40 
     
Visuospacial CI 4 16 20 
 NCI 12 8 20 
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 Totals 16 24 40 
     
Attention CI 3 13 16 
 NCI 13 11 24 
 Totals 16 24 40 
 
 
    
Delayed CI 0 16 16 
Memory NCI 16 8 24 
 Totals 16 24 40 
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3.6     Receiver Operating Characteristic and Area Under the Curve 
Conclusions 
 
Figure 2. ROC curve analysis for full battery neuropsychological testing and 
RBANS Total scale 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 11. AUC analysis for full battery neuropsychological testing and RBANS 
Total scale 
Area Under the Curve 
Test Result Variable: RBANS Total Index Score 
95% Confidence Interval 
Area Std. Error 
Asymptotic 
Sig 
Lower 
Bound 
Upper 
Bound 
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.963 .030 .000 .000 1.000 
 
 
 
 
 
Table 12. Optimum cut off scores for RBANS Total scale. 
 
Coordinates of the Curve 
Test Result Variable(s):RBANS 
Total Index Score 
Positive if 
Less Than 
or Equal To Sensitivity Specificity 
43.00 .000 1.000 
45.50 .030 1.000 
47.50 .061 1.000 
48.50 .091 1.000 
50.00 .121 1.000 
51.50 .152 1.000 
52.50 .212 1.000 
54.50 .242 1.000 
59.00 .273 1.000 
63.00 .303 1.000 
64.50 .333 1.000 
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65.50 .364 1.000 
66.50 .424 1.000 
67.50 .455 1.000 
68.50 .515 1.000 
70.00 .545 1.000 
72.50 .606 1.000 
74.50 .636 1.000 
76.00 .667 1.000 
79.00 .727 1.000 
82.00 .758 1.000 
83.50 .818 1.000 
85.00 .818 .857 
86.50 .848 .857 
88.50 .909 .857 
93.50 .939 .714 
97.50 .970 .714 
102.50 1.000 .714 
107.50 1.000 .508 
112.50 1.000 .429 
117.50 1.000 .286 
119.50 1.000 .143 
122.00 1.000 .000 
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Acceptable levels of sensitivity and 
specificity are highlighted. 
 
 
 
 
 
Figure 3. ROC curve analysis for full battery neuropsychological testing of 
immediate memory RBANS Immediate Memory Index. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 13. AUC analysis for full battery neuropsychological testing of immediate 
memory and RBANS Immediate Memory Index 
Area Under the Curve 
Test Result Variable: RBANS Immediate Memory Index 
Score 
95% Confidence Interval 
Area Std. Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
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.823 .073 .002 .679 .966 
 
 
 
 
 
 
 
 
Table 14. Optimum cut off scores for RBANS Immediate Memory Index. 
 
 
 
Coordinates of the Curve 
Test Result Variable(s):RBANS 
Immediate Memory Index Score 
Positive if 
Less Than 
or Equal To Sensitivity Specificity 
39.00 .000 1.000 
44.50 .091 1.000 
51.00 .182 .966 
55.00 .364 .966 
59.00 .545 .862 
68.50 .727 .739 
77.00 .727 .759 
79.50 .818 .724 
82.00 .818 .655 
85.00 .909 .552 
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88.50 .909 .517 
93.50 .909 .448 
98.50 .909 .414 
101.50 .909 .345 
104.50 1.000 .276 
107.50 1.000 .207 
111.00 1.000 .138 
115.00 1.000 .103 
118.50 1.000 .069 
121.50 1.000 .034 
124.00 1.000 .000 
Acceptable levels of sensitivity and specificity are highlighted 
 
 
Figure 4. ROC curve analysis for full battery neuropsychological testing of 
visuospatial  impairment and the RBANS Visospatial/Constructional Index. 
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Table 15. AUC analysis for full battery neuropsychological testing of 
visuospatial impairment and RBANS Visuospatial/Constructional Index 
Area Under the Curve 
Test Result Variable:RBANS Visuo/spacial Index Score 
95% Confidence Interval 
Area Std. Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
.966 .024 .000 .000 1.000 
 
 
 
 
Table 16. Optimum cut off scores for RBANS Visuospatial/Constructional Index. 
 
Coordinates of the Curve 
Test Result Variable(s):RBANS 
Visuo/spacial Index Score 
Positive if 
Less Than 
or Equal To Sensitivity Specificity 
39.00 .000 1.000 
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45.00 .042 1.000 
53.00 .333 1.000 
57.00 .375 1.000 
59.00 .542 1.000 
61.00 .583 1.000 
63.00 .667 1.000 
65.00 .708 1.000 
67.50 .708 .937 
72.00 .792 .937 
78.00 .875 .937 
82.50 .917 .812 
88.00 1.000 .750 
94.00 1.000 .687 
102.50 1.000 .500 
110.50 1.000 .437 
114.00 1.000 .312 
118.50 1.000 .187 
126.00 1.000 .062 
132.00 1.000 .000 
Acceptable levels of sensitivity and specificity are highlighted. 
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Figure 5. ROC curve analysis for full battery neuropsychological testing of 
attention and the RBANS Attention Index. 
 
 
 
 
 
 
 
 
 
 
 
 
Table 17. AUC analysis for full battery neuropsychological testing of attention 
and RBANS Attention Index. 
Area Under the Curve 
Test Result Variable: RBANS Attention Index Score 
95% Confidence Interval 
Area Std. Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
.757 .076 .006 .607 .907 
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Table 18. Optimum cut off scores for RBANS Attention Index. 
 
Coordinates of the Curve 
Test Result Variable: RBANS 
Attention Index Score 
Positive if 
Less Than 
or Equal To Sensitivity Specificity 
45.00 .000 1.000 
47.50 .048 1.000 
51.00 .143 1.000 
54.50 .190 1.000 
58.00 .238 1.000 
62.00 .333 .895 
66.00 .476 .842 
70.00 .571 .789 
73.50 .619 .789 
77.00 .667 .737 
80.50 .762 .632 
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83.50 .762 .579 
86.50 .857 .474 
89.50 .905 .421 
92.50 .905 .368 
95.50 .905 .316 
98.50 .905 .211 
101.00 .952 .211 
102.50 .952 .158 
104.50 1.000 .105 
117.00 1.000 .053 
129.00 1.000 .000 
Acceptable levels of sensitivity and specificity are highlighted. 
 
 
Figure 6. ROC curve analysis for full battery neuropsychological testing of 
delayed memory and the RBANS Delayed Memory Index. 
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Table 19. AUC analysis for full battery neuropsychological testing of delayed 
memory and RBANS Delayed Memory Index. 
 
Area Under the Curve 
Test Result Variable: RBANS Delayed Memory Index Score 
95% Confidence Interval 
Area Std. Error 
Asymptotic 
Sig. 
Lower 
Bound 
Upper 
Bound 
.817 .069 .001 .682 .952 
 
 
 
Table 20. Optimum cut off scores for RBANS Delayed Memory Index. 
 
 
Coordinates of the Curve 
Test Result Variable: RBANS 
Delayed Memory Index Score 
Positive if 
Less Than 
or Equal To Sensitivity Specificity 
39.00 .000 1.000 
42.00 .053 .952 
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46.00 .105 .952 
50.00 .263 .952 
54.00 .316 .952 
58.00 .368 .952 
62.00 .474 .857 
66.00 .526 .857 
69.50 .632 .810 
73.00 .737 .762 
76.50 .789 .714 
82.00 .895 .619 
90.50 .947 .619 
96.50 .947 .476 
100.00 .947 .333 
102.50 .947 .238 
106.50 1.000 .238 
111.00 1.000 .190 
113.50 1.000 .095 
117.00 1.000 .048 
120.00 1.000 .000 
Acceptable levels of sensitivity and specificity are highlighted. 
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3.7 Sample size calculation 
 
Based on the full battery overall conclusions for the prevalence rate of cognitive 
impairment following stroke, the sample size calculation would be: 
W = +/-0.10 
P = 0.80 
SN = 0.80 
SP = 0.90 
 
Calculate the Number with Disease, TP + FN: 
 
TP + FN = 1.96 x 1.96 0.8(1-0.8) 
                                       0.1x0.1 
 
    =  3.842 x 0.16 
           0.01 
     
    = 61.472 
 
Calculate the Sample Size Required for Sensitivity, N1: 
 
N1 = TP+FN 
              P 
 
      =    61.472 
               0.8 
 
      =   76 
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Calculate the Number without Disease, FP +TN: 
 
FP + TN = 1.96 x 1.96  0.9(1-0.9) 
                                        0.1x 0.1 
 
  =  3.842 x  0.09 
                    0.01 
= 34.578 
 
Calculate the Sample Size Required for Specificity, N2: 
 
N2 = FP+TN 
          (1 – P) 
 
      =  34.578 
             0.3 
 
      =  116 
 
 As N2 > N1, the statistically calculated sample size for overall cognitive 
impairment was 116 participants.  
 
Based on the domain specific index with the lowest prevalence rate (Immediate 
Memory) the sample size calculation would be: 
 
W = +/-0.10 
P = 0.30 
SN = 0.80 
SP = 0.70 
 
Calculate the Number with Disease, TP + FN: 
 
TP + FN = 1.96 x 1.96 0.8(1-0.8) 
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                                       0.1x0.1 
 
    =  3.842 x 0.16 
           0.01 
     
    = 61.472 
 
Calculate the Sample Size Required for Sensitivity, N1: 
 
N1 = TP+FN 
              P 
 
      =    61.472 
               0.3 
 
      =   205 
 
Calculate the Number without Disease, FP +TN: 
 
FP + TN = 1.96 x 1.96  0.7(1-0.7) 
                                        0.1x 0.1 
 
  =  3.842 x  0.21 
                    0.01 
= 80.682 
 
 
Calculate the Sample Size Required for Specificity, N2: 
 
N2 = FP+TN 
          (1 – P) 
 
      =  80.682 
             0.7 
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      =  115 
 As N1 > N2, the statistically calculated sample size for Immediate Memory was 
205 participants. 
4. EXTENDED DISCUSSION 
 
4.1 Further interpretation of results 
 
Analysis of the demographic variables indicated that age, gender and years of 
education were not normally distributed. With regard to age, this would be a 
reflection of the incidence of stroke increasing with age (Hankey, 2002) and 
would therefore follow the expected trend. Gender is reported to be unrelated to 
stroke incidence (Hankey, 2002) and therefore suggests that the sample in this 
study was biased towards male participants (N=25, 62% of sample). This may 
have been due to intrinsic gender differences in participation in research 
studies, though there is nothing in the literature to suggest that this might be the 
case (e.g. Harris & Dyson, 2001). A more likely explanation is that the three 
acute stroke wards from which participants were drawn from for this study are 
split between one mixed and two non-mixed wards, and that relationships 
between the ward staff and the researchers, or differences in ward practices, 
biased recruitment in favour of the male ward. This had an impact on the study 
results in that no female participants were identified as unimpaired, and 
therefore it could limit the generalisation of this study’s conclusions to the 
general population. However, in terms of calculating rates of sensitivity and 
specificity, this would not be a factor, as this is based on the characteristics of 
the test itself rather than the make up of the sample.  
 
The non-normal distribution of years of education may have been due to a 
cohort effect reflected in the bias within the sample towards people aged over 
65 as opposed to relatively fewer people recruited at an age when years of 
compulsory education was increased (Stuart-Hamilton, 2000). There was a 
statistically significant relationship between years of education and scores on 
both the RBANS and full battery. With regards to the RBANS, only age is 
controlled for within the normative data, and it has been argued that education 
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has a significant effect on neuropsychological test scores (e.g. Stuart-Hamilton, 
2000). Whilst years of education was estimated from the S-NART for the full 
battery, this was only used to control for norming on some of the tests (e.g. the 
COWAT). In clinical practice, years of education (as well as many other factors) 
would contribute to drawing conclusions from neuropsychological test results 
(Darby & Walsh, 2005), and this is an important consideration when considering 
the use of a screening test for post stroke cognitive impairment, in that the test 
score, regardless of its sensitivity and specificity, only has meaning when 
considered in light of a wider biopsychosocial understanding of a persons 
presentation. 
 
With regards to the potential effect of the relatively rapid spontaneous remission 
of cognitive impairments often seen following stroke (Johnstone & Stonnington, 
2001) having an impact on the results of this study, analysis of the data would 
suggest that this was well controlled for. Neither the RBANS or full battery test 
scores related to days from admission (r=0.13, p>0.4 and U=93, p>0.5 
respectively) or interval between testing (r=-0.18, p>0.2 and U=777.5, p>0.5 
respectively) suggesting that the days between testing (mean = 3.6 days, 
SD=4.6) was close enough to control against spontaneous remission effects, 
and this combined with the added control of alternating the administration of 
tests, suggests that the results presented in this study are measuring 
comparable clinical presentations.  
 
The results of this study suggested that the cut off score of 69 recommended by 
the RBANS manual as a classification of ‘Extremely Low’ (Randolph, 1998) 
appeared to be too low for accurate discrimination of impairment / non-
impairment for this sample as measured by the full battery testing with the 
exception of Immediate Memory. This may have been because the sample in 
this study was an unusual or atypical representation of the population. A 
possible explanation for this may have been that the patients who consented to 
participate were different to those who declined to participate, though because 
no data was recorded for the non-participants this is unknown. However, 
previous research would suggest that in comparable studies this has tended not 
to be the case in that there is little statistically significant difference between 
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those who consent and those who decline to participate (e.g. Nys et al, 2005).  
It could also have been because the full battery testing was not appropriate to 
discriminate impairment from non-impairment. This could be possible as the full 
battery was not extensive enough to measure all possible impairments due to 
the excessively high testing load that this would have placed on participants. A 
further explanation could be that the sample represented in this study was not 
from a community that was comparable to the normative sample for the 
RBANS. However, whilst possible, this too would seem an unlikely explanation 
as the hospital at which the study was conducted covered an extensive 
geographical area made up of diverse rural and urban communities. A more 
likely explanation is that the cut off scores identified by the manual provide only 
a guide to the general population and that this score is not applicable to a 
sample made up from stroke patients with (usually) focal impairments. Duff et al 
(2008) made similar conclusions when reporting optimum cut off scores for 
cognitive impairment in people with dementia. 
 
When using ROC identified optimum cut off scores, the cross tabulations 
suggested that the RBANS misdiagnosed 13 out of 40 (33%) participants on 
conclusions for Attention, as well as misdiagnosing 9 out of 40 (22%) 
participants on conclusions for Immediate and 11 out of 40 (27.5%) for Delayed 
Memory. The latter was slightly surprising given that the RBANS was developed 
as a screening test for dementia, where memory impairments are often 
highlighted. Again, whilst possible that this was due to a lack of diagnostic 
validity on the RBANS there are other potential reasons. Firstly, it is possible 
that given the small sample size, and especially the relatively small number of 
participants categorised as no cognitive impairment, these results were mere 
anomalies. It could also have been the case that the full battery tests lacked 
diagnostic validity, though this would appear to be unlikely as it would imply that 
the RBANS has better diagnostic validity than the full battery, and this in not 
reflected in the general body of literature in terms of the reliability and validity of 
all the tests outlined in the introduction. None the less, the Immediate Memory 
conclusions still represented adequate sensitivity (82%) and specificity (72%) at 
a cut off score of 79.5, and the Attention index demonstrated adequate 
sensitivity at 86%% at a cut off score of 86.5, though specificity was poor at 
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47%, probably related to the use of a motor task as discussed in the Journal 
Paper ‘Discussion’. 
  
It was also worth noting that the recommended cut off score for the RBANS 
Total scale was not particularly sensitive to overall conclusions for cognitive 
impairment, misdiagnosing 16 out of 33 (48%) categorised as impaired by the 
full battery tests, though it did not misdiagnose any participants as non-
cognitively impaired suggesting that the cut-off of 69 was too low (as opposed 
to measuring different constructs) even when compared to a cut-off of 5% on 
the full battery. However, the figure reduced to 6 out of 33 (18%) misdiagnosed 
when impairment was identified on any one of the index scores. This would 
indicate that the RBANS Total scale was not particularly sensitive to impairment 
the test itself identifies, when using a cut off of <69, potentially due to 
differences in labelling of cognitive domains (including, potentially, executive 
functioning) as discussed in the Journal Paper ‘Discussion’  
 
The results suggested that the RBANS was sensitive to executive functioning 
impairment, as suggested by Wilde (2006).  This was especially true of the 
Total Scale and Delayed Memory index of the RBANS. Ryusaku et al (2004) 
have argued that the underlying mechanism for memory loss in people with mild 
dementia (as measured by list learning tasks) is an impairment of executive 
functioning, and this may be what the Delayed Memory scale is sensitive to. 
The Total Scale may be measuring differing aspects of executive functioning as 
a more global construct, as discussed in the Journal Paper ‘Discussion’.  
 
Bearing in mind that there are limitations to this study resulting from the 
relatively small sample size, there remains the possibility that the RBANS could 
be a useful aid for clinical psychologists working with stroke patients. The 
results of this study were that the RBANS correctly identified 8 out of 10 
participants as being non-impaired on global cognitive conclusions. Given that 
the hospital where this study was completed admits approximately 800 stroke 
patients per year, this would mean that the RBANS would correctly identify 337 
patients as not requiring detailed investigation of potential cognitive impairment. 
This would still leave 299 stroke patients correctly identified as having a 
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cognitive impairment in at least 1 domain, and whilst this is a large number of 
people to complete in depth neuropsychological testing with, it is still 
substantially smaller figure than the 560 people predicted by the prevalence 
rate reported by Nys et al (2005). A further advantage of the RBANS is that its 
apparent sensitivity and specificity to specific cognitive impairment means that 
the neuropsychological testing may be appropriately guided towards focused 
investigations and consequently it could help to make best use of the clinical 
psychologists’ time and resources as well as identifying more rapidly those 
stroke patients who would benefit from more detailed neuropsychological 
investigation.  
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4.2 Implications for Clinical Psychologists working in stroke services 
 
The results presented here would suggest that the RBANS might be a valid test 
of diagnostic accuracy in screening for post stroke cognitive impairment. 
Diagnostic categories can be useful to clinical psychologists for three main 
reasons. Firstly, it can help to justify further interventions, as in stroke services 
where a score on a screening test would indicate the need for monitoring the 
cognitive status of the client, or the need for more detailed assessment. Clinical 
psychologists can also use this information to gather base rate data and to help 
inform the effectiveness of interventions. Secondly, some people (including both 
survivors of stroke and their families) can find having a diagnosis useful in 
understanding and coming to terms with difficulties experienced post stroke. 
Thirdly, and especially pertinent in an in-patient medical setting, diagnostic 
categories can aid communication with other professional colleagues, being 
used as a type of medical ‘short-hand’ (though difficulties in communication can 
occur when the interpretation of this short-hand differs between professional 
groups). Consequently, a test that demonstrates high levels of diagnostic 
accuracy can inform a part of both the direct and indirect work undertaken by 
clinical psychologists when working with survivors of stroke. 
 
Given the high prevalence rate of cognitive impairment following stroke, the 
RBANS high levels of specificity to global cognitive impairment can be useful to 
clinical psychologists in identifying people who do not require further 
assessment of cognitive impairment, as discussed above, and can therefore be 
of use in managing limited time and resources. However, a screening test of 
post stroke cognitive impairment could also be a useful resource for clinical 
psychologists working in stroke services in providing information on the type 
and severity of any identified impairment. Despite the RBANS being somewhat 
lengthier to administer compared to other comparable screening tests (such as 
the MMSE and ACE-R), it does have an advantage over these tests in that it 
can provide information that is clinically useful to a clinical psychologist. 
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Whilst diagnoses can be useful to clinical psychologists (as discussed above), 
in clinical practice they are more concerned with working with the individual and 
his or her idiosyncratic presentation. The impact of a stroke can be devastating, 
both for the individual and their families. However, the way a person reacts to 
this will depend not only on the nature, extent and severity of the stroke but also 
on many other factors including previous experiences, current thoughts, beliefs 
and interpretations, and their environment, including the provision of support 
(Darby & Walsh, 2005). Consequently, a screening test of post stroke cognitive 
impairment that has good levels of sensitivity to domain specific cognitive 
impairment is more useful to a clinical psychologist that a general measure of 
overall cognitive impairment. This information can then be useful (within the 
wider formulation) to hypothesise potential difficulties that the individual may 
face following stroke (provided that the test has adequate ecological validity, 
which has been reported as good for the RBANS with a stroke population by 
Larson et al, 2003) and to tailor specific, person centred interventions, usually 
focussed on compensation approaches which have been shown to help a 
person emotionally adjust to the consequences of stroke (Lincoln, 2005). 
 
Given that the results presented here suggest that the RBANS may have 
adequate sensitivity to the cognitive domains measured by its index scales (with 
the exception of attention as discussed above, and noting the lack of a specific 
index for executive functioning) the test would therefore be a useful additional 
resource for clinical psychologists working in stroke services. However, clinical 
psychologists are trained to make interpretations from such data (BPS, 2010), 
and the routine screening of survivors of stroke needs to be approached with 
some caution, as interpretation by clinicians unskilled in relating such test 
results to a persons individual presentation could result in incorrect conclusions. 
For instance, the data presented here would indicate that how many years of 
education a person has had will have an effect on the conclusions that can be 
drawn from the RBANS test results, or that a low score on the Attention index 
may be a result of motor difficulties rather that cognitive impairment. National 
guidelines suggest that clinical psychologists should be employed by stroke 
services to provide such expert interpretation (Department of Health, 2007), 
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though in the current financial climate cuts are a likely threat to the provision of 
this. However, cognitive impairment and its consequences following stroke 
would still remain a significant issue for a large number of people (Walford, 
Soljak & Majeed, 2009) and research into the screening of post stroke cognitive 
impairment would be justified in light of how this can be useful for clinical 
psychologists, stroke services generally (and by implication, for people who 
have had a stroke), and in continuing further research into the RBANS 
specifically given its potential clinical utility when compared to other similar 
screening tests.         
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4.3 Feasibility of Extended Study 
 
This pilot study was completed to establish the potential justification for and 
feasibility of conducting a full scale study into the diagnostic validity of the 
RBANS as a sensitive and specific screening test of post stroke cognitive 
impairment. As such, the results are presented as a tentative conclusion with a 
view to justifying (or otherwise) further research. Based on the results of this 
pilot (including the lack of specificity of the Attention index, which may be due to 
comparative difficulties with the full battery testing as outlined above) and taking 
into account the need for research into screening tests for post stroke cognitive 
impairment (as outlined in the introduction and also discussed in ‘Implications 
for Clinical Psychologists working in stroke’) it would appear that an extended 
study into the sensitivity and specificity of the RBANS as a screening test for 
post stroke cognitive impairment is justified. 
 
 The feasibility of an extended study is concerned with two general areas, the 
resource commitments and the impact of testing on participants, and there is 
significant overlap between the two. These considerations can be broken down 
further into: 
 
• Prevalence rates and sample size 
• Recruitment and consent 
• Adherence to ‘between testing’ timelines 
• Researcher commitments 
• Costs 
• Full Battery testing  
 
Prevalence rate and sample size 
 
Burderer (1996) argued that in order to be meaningful, the sample should reflect 
the prevalence rate of a particular disorder. As reported, the prevalence rate 
identified within is study is comparable with that of other studies. However, two 
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of these other studies (Cartoni & Lincoln, 2005, and Nys et al, 2005) had similar 
sample sizes to that reported in this study. Equally, there was a wide range of 
reported prevalence rates when taking into account all comparable studies 
(including Blake et al, 2002), a problem that is compounded when considering 
impairment in specific cognitive domains, where the sample of participants with 
a particular cognitive impairment is smaller than the overall impairment 
prevalence. This discrepancy could be due to several factors including those 
outlined in the introduction, such as differences in exclusion criteria or the use 
of differing ‘gold standard’ tests. It is thus difficult to estimate a sample size 
based on Burderer’s (1996) calculations without a greater consensus about 
prevalence rates. 
 
A complicating factor regarding the prevalence rate of cognitive impairment 
following stroke is that two of the published studies of evaluation of sensitivity 
and specificity have included evaluation of the MMSE (i.e. Blake et al, 2002, 
and Nys, 2005,). This study did not gather enough information regarding the 
MMSE to make reporting it useful. This was unfortunate as the conclusions of 
the MMSE, whilst not sensitive or specific to post stroke cognitive impairment, 
could provide a base rate from which comparisons with other studies might be 
drawn, especially given its ubiquitous use in clinical practice. It is interesting to 
note that Nys et al (2005) and Blake et al (2002) reported a prevalence rate of 
cognitive impairment following stroke of 35% and 31% respectively, with a cut 
off score of <24 though drew different conclusions. A further complicating factor 
in the estimation of prevalence rates for domain specific cognitive impairment is 
the heterogeneous nature of impairment following stroke. 
 
With these factors taken into account, the power calculations to give an 
adequate sample size presented in the results suggested that if an extended 
study was to focus exclusively on the RBANS as a sensitive and specific test of 
global post stroke cognitive impairment, then the sample would be 116 
participants. If an extended study were to examine the RBANS as a sensitive 
and specific test of domain specific cognitive impairment, then the sample size 
would be 205. In light of the discussions above, it would be recommended that 
the RBANS has greater clinical utility when used to screen for domain specific 
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cognitive impairment, and the recommendation would therefore be to recruit a 
sample of 205 
 
Recruitment and consent 
 
This pilot study had a consent rate of 47 out of 146 (32%) of people who met 
the inclusion / exclusion criteria, with a drop out rate of 7 out of 47 (14%). The 
drop out rate was comparable to other studies where this has been reported 
(e.g. Cartoni & Lincoln, 2005). It would appear that the consent rate was not 
affected by the time commitments or effort that participation entailed, and 
therefore other issues should be considered that might improve the consent 
rate. One of these would be to relax the exclusion criteria, and it would be 
recommended that the cut-off age of 80 be raised and the tests pro-rated to 
increase the pool size of potential participants. 
 
Adherence to ‘between testing’ timelines 
 
Ethical approval was given for the study to allow up to two weeks between 
RBANS and full battery test. However, the execution of this study placed a 
strong emphasis on completing the testing within as short a time period as 
possible. There are advantages and disadvantages to this approach. Keeping 
the timeline short meant that spontaneous remission was not a factor in the 
study results, and greater confidence could be placed in the assertion that the 
results reflected measurement of the same clinical presentation. However, a 
short timeline increases the potential risk of a practice effect influencing the 
results, and it also places a greater testing strain on participants. The latter 
however was not reported as being problematical by any of the participants in 
this study, and it would be recommended that the procedure employed by this 
study in relation to time between testing be retained. 
 
Researcher commitments 
 
The pilot study was conducted over a recruitment period of 26 weeks, though 
this did include holiday and study leave. Leave had an additional complication in 
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that when one of the two researchers was away, research had to stop as 
neither the Chief Investigator or the Research Assistant could complete both 
tests, as each had to be blind to the alternate test results. Given that 40 
participants completed all tests, this equated to an average recruitment of 1.5 
participants per week. With a suggested sample size of 205, this would equate 
to the study taking 137 weeks (2.6 years). The researchers each attended the 
stroke wards two days per week to complete testing. Testing was confined to 
short periods of the day due to several factors including participants attending 
groups or being seen by hospital staff, protected meal times, and visiting times. 
The Chief Investigator attended at weekends, which made administration of the 
full batteries easier as the wards were far less busy (the Chief Investigator also 
attended for a half day during the week to liase with ward staff and engage in 
participant recruitment). 
 
To conduct an extended study that recruited the suggested 205 participants 
would therefore require a major commitment from the research team. To some 
extent this could potentially be mitigated by the publishing of this pilot study. 
Given that previous research has been comparable to this pilot in terms of 
sample size and confidence intervals, it would appear appropriate to consider 
the current (albeit limited) research evidence as suggesting that the RBANS is a 
more clinically valid test of post stroke cognitive impairment than those currently 
being used for routine screening (for instance the MMSE). If the RBANS was 
administered as part of the routine intake assessment, then consent and 
recruitment would only be required to complete the full battery tests. This would 
halve the time commitment of the researchers, though it would have an effect 
on other variables such as managing the between testing time. The hospital at 
which this study was completed now uses the RBANS as an adjunct to other 
screening tests in that if no impairment is identified by the MMSE or MoCA, then 
the RBANS is administered to provide more detailed information. However, 
using the RBANS as a routine assessment tool would have financial 
implications for the host trust, and this would also be inappropriate if clinical 
psychologists were not routinely available to interpret the test results as 
discussed above.  
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Costs 
 
The cost of tests to complete this pilot study was £500, which came from a 
student research budget. This would make the cost of completing an extended 
study with 205 participants approximately £2700. The current study imposed no 
cost on the host trust as the Chief Researcher was employed by the NHS as a 
student, and the Research Assistants offered their time voluntarily. If similar 
arrangements could be found to complete an extended study then this would 
obviously keep costs down. Alternatively, funding could be applied for from 
other sources with the pilot being used as justification for extended research. 
 
 Full Battery testing 
 
A final consideration of the feasibility of conducting an extended study was the 
research utility and participant toleration of the full battery testing. These points 
have been considered elsewhere in the discussion, and to summarise, the full 
battery was well tolerated by the participants of this pilot (with none citing it as a 
reason for withdrawal) and it would be recommended that the full battery 
include a test of Attention that incorporated motor skills to make comparison 
with the RBANS more equitable (though it should be noted that the conclusions 
of the full battery would still maintain interpretation based on a test being void if 
it were influenced by non-cognitive factors, though the inclusion of an 
attention/motor task would allow incorporation of this variable to be included in 
the results). It would also be suggest that the Rey Figure be replaced with a non 
motor test of visual memory as discussed previously. 
 
 
Feasibility Summary   
 
An extended study into the sensitivity and specificity of the RBANS as a 
screening test of post stroke cognitive impairment is justified for the reasons 
outlined above. The feasibility of such as study would be dependent on the 
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provision of resources in terms of research staff and financing, and would 
require a relatively substantial commitment. Suggestions have been made 
above to make changes to the study design that could have some effect in 
reducing the commitment needed without compromising the quality of the 
research, and it is suggested that given the need for a sensitive and specific 
screening test of post stroke cognitive impairment, and the potential evidenced 
in this pilot study for the RBANS to be suitable in this role, an extended study 
would be recommended.            
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4.4  Critical reflection 
 
The design of this study was carefully considered (with credit for that going 
mainly to the research supervisor) and discussed with supervisors and others 
before being undertaken, and appeared to be appropriate for the research 
question being asked. The basic design was also similar to other studies asking 
the same research questions of differing screening tests (i.e. Blake et al, 2002, 
Cartoni & Lincoln, 2005, and Nys et al, 2005). As such, the conclusions of this 
study can be confidently interpreted as being related to the research question, 
and the results can be readily compared to other research (though this does not 
imply that the results can be confidently interpreted without reference to the 
limitations of the study, such as the relatively small sample size and large 
confidence intervals). Nonetheless, despite such a seemingly well-designed 
study, the practical execution of the research highlighted several complications 
that were unanticipated by the author and that led to various learning points. 
 
The first of these concerned the timeline of the study, in that ethical approval 
took far longer to be granted by the local REC than expected. This was due to 
the author relying too heavily on previously published research to guide the 
ethics application, and not being mindful of basic premises of the research 
process, especially with regards to completing a formal power calculation to 
estimate the required sample size. 
 
 The reason for having a representative sample is to allow for greater 
generalisability of the results to inform clinical practice. There is thus an ethical 
dimension to having an adequate sample size, in that the people who 
consented to participate should have done so for a useful purpose. As Burderer 
(1996) makes clear, too small a sample size may result in imprecise estimates 
of sensitivity and specificity, and if the sample does not reflect the disorder 
prevalence rate of the population for which the test is designed to screen, then 
the information resulting from the study may be misleading. This was rectified 
by completing the study as a pilot in order to establish the justification for and 
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feasibility of conducting an extended study into the sensitivity and specificity of 
the RBANS as a screening test of post stroke cognitive impairment. This would 
allow evaluation of participant consent rates, the likelihood of anticipated time 
scales being adhered to (in terms of duration between testing), the tolerability of 
the testing load on participants, and the identification of unforeseen resource 
requirements. The learning point here was that in preparing for this study the 
author placed too great an emphasis on consulting previously published 
literature, and that research practices that have become established over time 
can become regarded as constituting clinically applicable or acceptable 
research, and that stepping outside of this practice can be difficult and anxiety 
provoking. However, the consequences of not doing so can not only lead to 
delays in the research being completed (a relatively minor consequence) but it 
can also lead to ethically questionable research being published and used to 
influence clinical practice. Whilst this did not have had any particular impact of 
the overall design of this study it did mean that the research was delayed, and 
that in the future the author would seek ethical approval at an earlier point in the 
process. 
 
A further learning point related to working with the ward staff. Whilst weekly 
meetings were held between the chief investigator and members of the ward 
staff, to aid in identifying potential participants, these tended to be relatively 
informal and on an ad hoc basis. A consequence of this was that a large 
proportion of participants were identified away from these meetings, usually in 
discussion with the ward sisters or by speaking to one of the Occupational 
Therapists. Whilst this research would not have been a high priority for the ward 
staff, and therefore allocating time to formal research meetings would be 
inappropriate, given the number of different studies taking place it may have 
been appropriate to have had a more organised approach to liasing between 
the various researchers and the ward staff. This could have been organised to 
take place during a staff handover followed by a meeting between the various 
researchers. This could potentially have prevented patients being approached 
by numerous researchers, and would have allowed a more equitable and 
focused approach to participant recruitment. 
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A final criticism of the research process was the way in which the tests were 
administered. These tended to take place at the patients bedside, and were 
often affected by disturbances on the ward and by staff interruptions. Whilst it 
may have been appropriate for the RBANS to have been completed at the 
bedside (as this would reflect the clinical practice of administering a screening 
test on an acute in-patient setting) it might have been more appropriate for the 
full battery to have been completed somewhere more conducive to 
neuropsychological testing. This would have been difficult to arrange for several 
reasons, including often a lack of participant mobility and limited room space. 
However, a system could have been organised to book the clinical psychology 
office based on one of the wards, and with planning and liasing with ward staff, 
arrangements made for the participant to come to the room for testing. This 
would have made the testing process more reliable, and may have made it 
more comfortable and enjoyable for the participants. 
 
The author took a positivist epistemological position. This is to say that the 
philosophical stance underlying this study was that there is an objective truth 
underpinning all phenomena, and that this truth can be identified and quantified 
through scientific investigation. Whilst there are criticisms of such an approach, 
such as positivism leading to a narrow and artificial understanding of human 
behaviour and experience (Coolican, 1990), the author believes that such 
criticisms, whilst potentially valid, relate more to our lack of understanding of 
such phenomena rather than with problems with the scientific approach itself. 
Also, positivism is the dominant paradigm underpinning other research related 
to this study, and though it might have been appropriate to explore this from an 
alternative viewpoint, the purpose of this study was to explore gaps within the 
existing approach. 
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4.5    Future research 
 
Future research into the evaluation of the diagnostic validity of the RBANS 
could potentially benefit from employing variations on the research design used 
in this study. The current study used the normative data provided by Randolph 
(1998) on which to base its conclusions for cognitive impairment /non-
impairment. Difficulties with this approach have been highlighted above, and an 
alternative design would be that used by Nys et al (2005) who recruited a 
matched sample from which to compare the RBANS conclusions. An advantage 
of a matched control design is that the comparative sample from which the 
conclusions for cognitive impairment / non-impairment are drawn are potentially 
better representative of the research sample being investigated, and thus 
removing the possibility of comparison with a non-representative normative 
base as discussed above. This would be a considerable advantage when 
investigating the diagnostic validity (as opposed to the clinical utility) of the 
RBANS. However, the converse is also true, in that the reported results would 
not relate as closely to ‘real life’ clinical practice, where access to a matched 
control sample would be impossible. 
 
There are also other disadvantages to using a matched control design. Firstly, 
this type of design would add a significant logistical burden to the recruitment 
and testing process. Secondly, the problem remains that if the research sample 
is small, the results may not be generalisable to the wider stroke population. 
Thirdly, if cognitive impairments are identified within the control population, and 
these results mean that this participant is withdrawn (as in the Nys et al, 2005 
study) where is the cut off point made? And related to this, identification of 
cognitive impairment / non-impairment in the control group would be taken from 
the normative data, which in effect would mean that the normative data was 
being applied to the experimental group once removed. Finally, the recruiting of 
a matched control sample could add in an extraneous variable in the form of the 
motivation of the matched controls to participate in the study. Rarely do 
research papers have the space to report these kinds of details, and Nys et al 
(2005) did not report on their recruitment strategy for their control group.  
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A further consideration for an alternative design to the one used in this study 
would be to have improved standardisation of the ‘gold standard’ testing. 
Having a fixed battery approach, as opposed to a flexible battery approach, 
would have the advantage of providing a baseline from which to compare other 
similar studies (Lezak, 2004). However, this would have the effect of distancing 
the research results from clinical practice. An alternative design would be to use 
blinded neuropsychological consensus (Duff, 2008), though it would be difficult 
to control for confounding variables such as potential workplace cultural 
differences. Ultimately, the evaluation of the diagnostic validity of a screening 
test is essentially independent of its clinical use, and so the development of a 
standardised ‘gold standard’ battery would be of immense value in researching 
a diagnostically valid screening test of post stroke cognitive impairment. 
 
It would be useful to identify redundant sub-tests within the RBANS to help 
make it slightly more ‘user friendly’. Whilst the reported experience of 
participants within this study was that the RBANS was generally well tolerated, 
there were 2 participants who could not complete the test in the acute stage of 
recovery from stroke. One if these participants later withdrew from the study, 
and the other completed the RBANS 2 weeks later. Whilst the RBANS was a 
usable bedside screening test, anything that would reduce the testing load on 
the patient or increase the brevity and portability of the test, whilst maintaining 
adequate levels of sensitivity and specificity, would be an advantage. Finally, 
the results presented here would suggest that further evaluation of the RBANS 
as a sensitive and specific screening test of post stroke cognitive impairment is 
warranted.   
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Appendix A – Journal Author Guidelines 
International Journal of Stroke  
Author Guidelines 
The journal to which you are submitting your manuscript employs a 
plagiarism detection system. By submitting your manuscript to this 
journal you accept that your manuscript may be screened for plagiarism 
against previously published works. 
The aim of the International Journal of Stroke is to concentrate on the clinical 
aspect of stroke with basic science contributions in areas of clinical interest, 
and to collate from varying sources, information from all around the world, for 
the benefit of our readership. 
The International Journal of Stroke is a peer reviewed journal. All manuscripts 
will be reviewed by leaders in the appropriate field. 
WORD LIMITS 
- Review manuscripts should be between 4000-8000 words, including 
references. 
- Research (previously known as Original articles) should be between 5000 
words, including references and any tables. 
- Leading Opinion manuscripts should be up to 1000 words, including 
references. 
- Panorama manuscript should be up to 1000 words, including references. 
- Protocols should be between 2000-5000 words, including references and 
any tables or diagrams you may wish to include. 
- Guidelines should be between 3000-5000 words, including references. 
All manuscripts are considered for publication with the understanding that they 
are submitted to this journal only and have not been published, submitted 
simultaneously (or accepted for publication) elsewhere; that they are the 
original work of the author(s); and that they may not be reprinted without the 
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consent of the International Journal of Stroke. Documents should be double 
spaced throughout. 
RESEARCH ARTICLES (formerly known as Original Articles) SHOULD 
BE STRUCTURED IN THE FOLLOWING WAY: 
Documents should be double spaced and structured in the following order: 
1.Title page 
- Title 
- Author name(s) 
- Affiliation(s) 
- Address of all authors 
- Name, address and email of corresponding author to be clear 
2. Abstract 
Provide a structured abstract according to the following headings: 
- Background 
- Aims and/or hypothesis 
- Methods 
- Results 
- Conclusions 
3. Introduction 
4. Aims and/or Hypothesis 
5. Methods 
6. Results 
7. Discussion 
8. References 
9. Figures, Tables and Illustrations 
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REFERENCES 
These must be limited to the work cited in the paper and should not be a 
bibliography of the subject. Personal communications and unpublished 
material ARE NOT ACCEPTABLE as references. Each reference should 
conform to the Vancouver style, and references should be numbered 
consecutively in the order in which they are first mentioned in the text. List all 
authors (include all initials) when there are six or fewer; when seven or more, 
list the first three and add 'et al'. Give the title of the paper in full; the title of the 
journal abbreviated according to PubMed; the year; the volume number and 
the first and last page numbers of the article. Examples: 
Standard journal 
Siebke H, Breivik H, et al. Survival after 40 minutes submersion without 
cerebral sequel. Lancet 1995;1:1275-77. 
Section of a book 
Talley NJ, O'Connor S. Clinical Examination. 5th ed. Minnesota: Churchill 
Livingstone, 2005;114-17 
Chapter in a book 
Buckley WE, Nunn T. A rational response to the threat of bioterrorism. In: 
Plant GW, Blair A, Winston JH Jnr, editors. Primary care in the third 
millennium. Washington: R McGeddon Inc., 2006;457-72. 
Website 
Bank of Tanzania. Tanzania: Economic and Financial Indicators. Dar es 
Salaam, Tanzania: Bank of Tanzania 
http://www.bot-tz.org/Publications/EconomicIndicators/E... (accessed on Jan 
23, 2007). 
FIGURES, TABLES AND ILLUSTRATIONS 
Illustrations are encouraged for their educational value. Diagrams, line 
drawings, photographs or fl ow charts are valuable but their use will be subject 
to editorial judgment. Photographic illustrations and diagnostic imaging media 
must be supplied in electronic form. The only acceptable format is Tiff or 
JPEG file, at 300 dpi. 
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Go to http://authorservices.wiley.com/bauthor/illustration.asp for author 
guidelines on electronic artwork. 
 
Tables must supplement the text without duplicating it. Each should be 
numbered, typed on a separate electronic sheet, and have an appropriate title, 
all manuscripts must be in basic Word format, PDF files cannot be accepted. 
Please do not create tables as a JPEG file if it can be avoided. They need to 
be in word format for editing purposes. 
Writing tips for authors 
These 12 golden rules may assist you with your manuscript, professional 
writers and editors from around the world use these as their guide. 
 
1. Write and edit to express yourself clearly. Do not use flowery or verbose 
language. 
2. Always write and edit your text so that everything can be understood. 
3. Always write and edit your work so that nothing can be misunderstood. 
4. Say what you mean to say, clearly and simply. 
5. Use short sentences. 
6. Use short paragraphs. 
7. Use the shortest, simplest words possible. 
8. Write in the active voice. 
9. Avoid unnecessary words. 
10. Use verbs for action. 
11. Avoid clichés and jargon. 
12. If in doubt, leave it out. 
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         5 Sydney Street 
         Boston 
         Lincs 
         PE21 8NZ 
 
                 Tel: 01205 354977 
                        07904 524504 
 
      email: 08127475@students.lincoln.ac.uk 
 
         12th April 2010 
 
Dear Mr Hopkinson 
 
Regarding: REC reference number 10/H0401/15 
 
Study title: Evaluation of the Repeatable Battery For The Assessment Of                       
Neuropsychological Status (RBANS) for screening for cognitive impairment 
following stroke. 
 
      Your review letter dated 25th February 2010.  
 
Thank you for your letter outlining the committee’s provisional opinion and requests for 
further information and clarification. Enclosed are revised versions of the research 
proposal, Patient Information Sheet, and Consent Forms: all changes and amendments 
are highlighted in red.  
 
Regarding the requests for further information or clarification, these are as follows: 
 
1. Test results should be made available to patients and their families. 
 
The test results will be recorded in the patient notes and made available to patients and 
their families.  
 
2. The sample size should be estimated on the primary aim. A power calculation 
should be carried out and justification should be given for the inclusion of the 
Lincoln site if recruitment targets can be met at the Nottingham site. 
 
Power calculations to determine the sample size do not exist for evaluations of 
sensitivity and specificity. This is because the sample size needed is dependent 
on the prevalence of the disorder (e.g. cognitive impairment) within the sample, 
which can only be calculated after the sample has been tested (i.e. post hoc). 
The sample size has therefore been estimated based on previous research 
sample sizes, the expectation that cognitive impairment is present in 
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approximately 70% of people following stroke, and in line with how sample sizes 
have been estimated for previous research with equivalent designs. The sample 
size arrived at (30) is a minimum sample size (taking into account projected 
drop out) to give clinically useful information, with the literature reporting a 
median sample size of 118. The inclusion of the Lincoln site would increase the 
number of potential participants to 60 (i.e. 30 per site), bringing the sample size 
for this study closer in line with the reported median sample size, and meaning 
that by including two sites, we could gather the data in less time. Including an 
additional site would also make the findings of the study more generalisable, as 
the results would not be specific to a single ward. 
 
The Lincoln site can only be included if the patients are also recruited for testing 
the primary aim (i.e. comparison vs full battery test) 
 
Full battery tests will be administered at the Lincoln site, completed by an 
Assistant Psychologist under the clinical supervision of Dr Vanessa Dale. This 
amendment is highlighted in the revised proposal (version 2, dated 29th March 
2010). 
 
3. The following additions/revisions are required on the Participant Information 
Sheets (PIS) 
 
The listed additions/revisions have been completed – please see enclosed PIS 
(version 2 dated 29th March 2010). 
 
With specific reference to item b (an upper age limit should be included to 
correspond with age validated tests), the upper age limit has been set at 80 
years, as there is good normative data for all the tests up to this age. 
 
With specific reference to item c (provide a full explanation of how long the tests 
take to complete, the name and the total number of the questionnaires to 
complete) the tests comprising the full battery are made up of sub-tests of 
longer tests, to give specific measures of the domains of cognitive impairment 
under investigation (rather than subjecting the participant to lengthy and 
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unnecessary full testing). The full list of tests/sub-tests have been included on 
the PIS and are detailed in the proposal (v2, 29th March 2010).  
 
4. The title on the consent forms should be consistent with the one used on the 
PIS. 
 
These are now consistent – please see enclosed consent form and PIS (v2, 29th 
March 2010). 
 
5. Remove the participant’s name from the RBANS questionnaire and assign a 
study ID instead. 
 
A study ID will be used instead of the participant’s name on the RBANS, 
consistent with the study ID allocated on the consent form. 
 
The participant’s personal details in answer to the questions should not be 
recorded on the questionnaire. 
 
These questions will not be asked (as they do not form part of the scoring) and 
therefore not recorded on the questionnaire. 
 
6. The tests should be randomised as to which will be carried out first and a 
question “Has your medical condition changed from the last time you completed 
the questionnaires?” should be added when the second set of questionnaires is 
completed. 
 
These changes have been made to the design and procedure and are 
highlighted in the amended proposal (v2, 29th March 2010). 
 
7. Explanation on the statistical analysis is needed, i.e. if they are estimating the 
positive and negative predictive value. 
 
Positive and negative predictive values will be calculated and are highlighted 
under data analysis in the amended proposal (v2, 29th March 2010). 
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8. To clarify the cut-off points for each questionnaire in the battery tests for 
determining cognitive impairment. 
 
A cut-off score of lower than the 5th percentile (for age adjusted norms) will be 
used to determine cognitive impairment on each of the battery tests, in line with 
standard practice (amendment highlighted under data collection in the revised 
proposal v2, 29th March 2010). 
 
9. Clarify if the storage time is 12 months (A43) or seven years as it is 
mentioned at PIS. 
 
The data will be securely stored on the ward for a maximum of 12 months, until 
the research has been completed, then securely stored at the University of 
Lincoln for 7 years in line with University research guidelines.   
 
Please note that because of the change to randomise the order of 
administration of the RBANS/full battery tests, consent will not automatically be 
taken by the chief investigator but by the person who will administer the first set 
of tests (i.e. this could be the Assistant Psychologist who will administer the full 
battery tests). The Assistant Psychologist has experience of research to a 
minimum of undergraduate degree level (as outlined in the IRAS form) and will 
be working under the direct supervision of a Clinical Psychologist (Dr. Vanessa 
Dale). The process for ascertaining capacity to give informed consent will 
remain as before. Also, the procedure in the proposal has been amended to 
reflect the change of having the same procedure at both sites (i.e. there is now 
only one standard procedure - see point 2 above).  
 
If I can be of any further assistance, please do not hesitate to contact me. 
 
Yours sincerely 
 
Steve Green 
Chief Investigator.  
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         5 Sydney Street 
         Boston 
         Lincs 
         PE21 8NZ 
 
                 Tel: 01205 354977 
                        07904 524504 
 
      email: 08127475@students.lincoln.ac.uk 
 
         22nd May 2010 
 
Dear Mr Hopkinson 
 
Regarding: REC reference number 10/H0401/15 
 
Study title: Evaluation of the Repeatable Battery For The Assessment Of                       
Neuropsychological Status (RBANS) for screening for cognitive impairment 
following stroke. 
 
      Your review letter dated 13th May 2010.  
 
Thank you for your letter outlining requests for further information and clarification. 
Enclosed are revised versions of the research protocol (v3), Patient Information Sheet 
(v3), Consent Form (v3), amended RBANS, and List of Full Battery tests: all changes 
and amendments are highlighted in red.  
 
Regarding the requests for further a more complete response, these are as follows: 
  
 
2. The sample size should be estimated on the primary aim. A power calculation 
should be carried out and justification should be given for the inclusion of the 
Lincoln site if recruitment targets can be met at the Nottingham site. 
 
We have taken advice from Graham Warren (statistician, University of 
Nottingham) and have used the power calculation to estimate the sample size 
taken from Buderer (1996). Previous research has indicated that several directly 
comparable screening tests have good levels of specificity (please see Protocol 
v3 Introduction), and it is estimated that the RBANS will be similar, with an 
expected specificity of 90%. What is currently missing is a screening test that 
provides adequate sensitivity. To be considered clinically useful, a sensitivity 
level of 80% is considered appropriate. The sample size calculation is based on 
a 95% confidence interval with a width of 10%, and an estimated prevalence of 
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cognitive impairment of 70%. This calculation gives a sample size of 116, taken 
from the higher figure, which is for specificity, as per Burderer (1996). (The full 
calculation and justification is highlighted in the revised protocol, version 3, 
under Sample Size).   
 
The inclusion of the Lincoln site is requested as this would allow access to a 
greater number of potential participants, as well as allowing for unforeseen 
eventualities (such as ward closures) and to counteract the expected high drop-
out rate. The inclusion of a second site would also have the advantage of 
allowing greater generalisability of the results, as it would balance potential 
confounding variables such as particular ward procedures.   
 
The Lincoln site can only be included if the patients are also recruited for testing 
the primary aim (i.e. comparison vs full battery test) 
 
Full battery tests will be administered at the Lincoln site, completed by an 
Assistant Psychologist under the clinical supervision of Dr Vanessa Dale, as 
described in the previous letter dated 12th April 2010. 
 
3. The following additions/revisions are required on the Participant Information 
Sheets (PIS) 
 
c provide a full explanation of how long the tests take to complete, the name 
and the total number of the questionnaires to complete – clarification on the 
completion time of each tests battery is needed 
 
Many of the full tests would take between 30-40 minutes to complete in their 
totality. However, we will only be administering selected sub-tests (as detailed 
in the Protocol and PIS) to provide the specific data required for the study. 
These sub-tests should take no longer than the time indicated in the protocol 
and the PIS. Many of the tests have a discontinuation rule, meaning that for 
some participants completion will be faster than for those who complete the full 
sub-test, hence the range in completion times. Enclosed is a more detailed and 
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complete version of the List of Full Battery Tests indicating the specific sub-
tests that will be used, as well as accompanying published information. 
 
 
5. Remove the participant’s name from the RBANS questionnaire and assign a 
study ID instead. 
 
A study ID will be used instead of the participant’s name on the RBANS, 
consistent with the study ID allocated on the consent form. Please see enclosed 
copy of RBANS. 
 
 
Regarding your requests for further clarification: 
 
1. Is the completion time for the RBANS 20-30 minutes as per the protocol or 
15-20 minutes as per the PIS? 
 
Completion time for the RBANS is 20-30 minutes. The PIS (v3) has been 
amended accordingly. 
 
2. Will the alternative tests be completed again within 2 weeks as per the 
protocol, or within 1 week as per reply to provisional opinion letter? 
 
The alternative tests will be completed within 2 weeks of the original testing as 
per the Protocol. 
 
3. Evidence of GCP or training in informed consent is needed for the Assistant 
Psychologist, who will also be taking informed consent. 
 
The Assistant Psychologist does not at present have formal training in informed 
consent, though assessing for capacity to give informed consent has formed 
part of her academic studies. Formal GCP training will be completed by the 
Assistant Psychologist before data collection begins, and she will not see any 
patients before it has been completed. 
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If I can be of any further assistance, please do not hesitate to contact me. 
 
Yours sincerely 
 
 
 
Steve Green 
Chief Investigator.  
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Appendix C – Participant Information Sheet and Consent Form 
 
 
 
 
Patient Information Sheet 
 
Title of project: Study to evaluate the Repeatable Battery for the 
Assessment of Neuropsychological Status (RBANS) for detecting 
cognitive impairment after stroke. 
 
Researchers: S Green, M Gresswell, N Lincoln 
 
We would like to invite you to take part in this research study. Before you decide 
you need to understand why the research is being done and what it would 
involve for you. One of our team will go through this information sheet with you 
and answer any questions you may have. 
 
Talk to others about the study if you wish.  
 
Part 1 of this information sheet tells you the purpose of this study and what will 
happen to you if you take part. 
 
Part 2 gives you more detailed information about the conduct of the study. 
 
Ask us if there is anything that is not clear or if you would like further 
information. Take time to decide whether or not you wish to take part.  
 
The study is part of a doctoral training programme in clinical psychology. 
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Part 1 
WHAT IS THE PURPOSE OF THE STUDY AND WHAT WILL HAPPEN TO 
YOU IF YOU TAKE PART? 
 
 
What is the purpose of the study? 
 
The study aims to investigate whether a test called the RBANS can identify 
specific problems with thinking and memory in people who have suffered from a 
stroke. It is hoped that this test will be better at identifying these problems than 
other tests that are currently used. 
 
Why have I been invited? 
 
You have been invited to take part in this study because you have recently been 
admitted to the stroke ward and the staff on the ward have identified you as 
being someone who might be able to complete the questions on the test. You 
will only be able to take part if you are aged 80 or under, as some of the tests 
used in the study may not be reliable for people over this age. 
 
Do I have to take part? 
 
No, it is up to you to decide. We will describe the study and go through this 
information sheet with you. We will then ask you to sign a consent form to show 
you have understood what is involved and agreed to take part. You are free to 
withdraw from the study at any time, without giving a reason. This will not affect 
the standard of care you receive. 
 
 
What will happen to me if I take part and what will I have to do? 
 
If you decide you would like to take part you will be asked to complete two sets 
of tests.  
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The first of these tests, called the RBANS, will be done with a member of the 
research team. This test involves answering questions, for instance how many 
items you can remember from a list, and takes 20 to 30 minutes to complete. 
This test can be done at your bedside.  
 
The second set of tests will be done with a different member of the research 
team. These are a more in-depth set of tests and are known as a test battery. 
This battery is made up of: 
 
• Rey-Osterreith Complex Figure (approximately 5 minutes to complete) 
• Wechsler Memory Scale III Logical Memory I  (5 minutes) 
• Visual Object and Space Perception Test (10 – 20 minutes) 
• Behavioural Inattention Test star cancellation (5 minutes) 
• Shortened National Adult Reading Test  (5 – 10 minutes) 
• Controlled Oral Word Association: FAS test (5 minutes) 
• WMS III Digit Spatial Span (5 minutes). 
• WMS III Letter Number Sequencing (5 minutes) 
• WMS III Logical Memory II (5 minutes) 
• Rey-Osterreith Complex Figure immediate recall (5 minutes) 
• Rey-Osterreith Complex Figure delayed recall (5 minutes) 
• Modified Card Sorting Test (5 – 10 minutes)  
• Brixton Spatial Anticipation Test (5 minutes) 
 
It is expected that these tests will take a maximum of 1 hour 30 minutes to 
complete, and you will be able to take breaks whenever you wish. These tests 
will be done in a side room on the ward, or if you have been discharged we may 
ask to visit you at your home to complete them. 
 
You may be asked to complete either the RBANS or the battery tests first, and 
the other tests will be completed a few days later.  
 
1011, RES, UofN: 4092661, UofL: 08127475, Thesis  
 Page 164 of 169 
The two sets of tests are used to measure strengths and weaknesses in a 
persons thinking and memory. The results of these two tests will be compared 
to see if they agree on the strengths and weaknesses that they have or have 
not identified.  
 
The study will last for about 18 months, though your involvement will only take a 
week or two, long enough to arrange to complete the two tests.   
 
 
What are the tests being investigated? 
 
When you were first admitted to the ward, one of the tests you would have done 
was called the Mini-Mental State Examination (MMSE), which is one of the most 
commonly used tests to check for possible difficulties in memory and thinking. 
The Repeatable Battery of Neuropsychological Status (RBANS) is a newer and 
slightly more in-depth test. Both tests are used to identify areas of thinking and 
memory that might require further investigation, and have been shown to be 
good at doing this in patients who have other problems. It is not known how 
good they are at identifying these problems in people who have had a stroke. 
The results from the in-depth tests will be used to compare with the results of 
the MMSE and RBANS to see how good these are at identifying strengths and 
weaknesses. 
 
What are the disadvantages and risks of taking part? 
 
Doing the tests can take up to one and a half hours, though you will be able to 
take breaks whenever you need to.  
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What are the possible benefits of taking part? 
 
It is unlikely that the study will help you directly but we hope that the information 
we get from this study will help to improve the treatment of people who have 
had a stroke. 
 
 
 
What if there is a problem? 
 
Any complaint about the way you have been dealt with during the study will be 
addressed. The detailed information on this is given in Part 2. 
 
Will my taking part in the study be kept confidential? 
 
Yes. We will follow ethical and legal practice and all information about you will 
be handled in confidence. The details are included in Part 2. 
 
If the information in Part 1 has interested you and you are considering 
participation, please read the additional information in Part 2 before making any 
decision. 
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Part 2 
DETAILED INFORMATION ABOUT THE CONDUCT OF THE STUDY 
 
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any time, without giving a reason. If you do 
not wish to continue in the study then any test scores that we have already 
collected will be identified as yours and withdrawn. 
 
What if there is a problem? 
 
If you have a concern over any aspect of this study, you should ask to speak to 
the researchers who will do their best to answer your questions – you can do 
this by asking the ward staff or telephoning directly on 01522 886029. If you 
remain unhappy, or wish to make a formal complaint, you can do this by 
contacting the supervisors of this study (contact details are provided at the end 
of this information sheet) or through the NHS Complaints Procedure by 
contacting the local Primary Care Trust (Nottingham City PCT) on 0115 845 
4545 (the full address is provided at the end of this information sheet). 
 
Will my taking part in this study be kept confidential? 
 
All information which is collected about you during the course of the research 
will be kept strictly confidential. The results of your tests will be given an 
anonymous identification number, and the collected data will be kept in a 
password protected master file. Only the research team will be able to identify 
you by your identification number. The test sheets will be kept securely filed on 
the ward throughout the study, and then securely filed at the University of 
Lincoln until they are destroyed in 7 years time.  
 
What will happen to the results of the study? 
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It is hoped that the results of the study will be published in an academic journal, 
so that clinicians involved in working with people who have had a stroke can 
make more informed decisions about which tests to use when assessing for 
strengths and weaknesses in thinking and memory.  
 
Who is organising and funding the study? 
 
The study has been organised by the Trent Doctorate in Clinical Psychology, 
which is run by the Universities of Lincoln and Nottingham, and is funded by 
Lincolnshire Partnership NHS Foundation Trust, Nottinghamshire Healthcare 
NHS Trust, and Derbyshire Mental Health Services NHS Trust. The study has 
been reviewed by the Derbyshire Research Ethics Committee.  
 
 
 
 
Further information and contact details 
 
If you would like further information about how Psychologists do research, this 
can be found on the British Psychological Society website Research and 
Science page at www.bps.org.uk   
 
If you would like further support or information about strokes you can contact 
the Stroke Association on 0845 3033 100 or email info@stroke.org.uk 
 
If you would like further information about this research project please contact: 
Steve Green (Chief Investigator),  
C/o University of Lincoln, 
Health, Life and Social Sciences,  
Court 11, Satellite Building 8,  
Brayford Pool,  
Lincoln LN6 7TS  
Telephone 01522 886029. 
 
Study supervisors: 
 
Dr Mark Gresswell (Academic Supervisor) 
University of Lincoln, 
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Health, Life and Social Sciences,  
Court 11, Satellite Building 8,  
Brayford Pool,  
Lincoln LN6 7TS  
Telephone 01522 886820 
 
Professor Nadina Lincoln (Research Supervisor) 
Institute of Work, Health & Organisations, 
University of Nottingham, International House, 
Jubilee Campus, 
Wollaton Road, 
Nottingham NG8 1BB 
Telephone 0115 9515315 
 
Local Primary Care Trust: 
 
Nottingham City PCT 
1 Standard Court, 
Park Row 
Nottingham 
NG1 6GN 
Telephone 0115 845 4545 
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REC Reference Number: 10/H0401/15 
Patient Identification Number: 
 
 
CONSENT FORM 
 
Title of project: Study to evaluate the Repeatable Battery for the Assessment of 
Neuropsychological Status (RBANS) for detecting cognitive impairment after 
stroke. 
 
Name of Researcher: Steven Green, University of Lincoln     
Academic Supervisor: Dr. Mark Gresswell, University of Lincoln  
Clinical Research Supervisor: Prof. Nadina Lincoln, University of Nottingham                   
                          
Please            
initial box 
 
1. I confirm that I have read and understand the information sheet (dated 
22nd May 2010, version 3) for the above study. I have had the opportunity to 
consider the information, ask questions and have had these answered 
satisfactorily.         
  
 
2.  I understand that my participation is voluntary and that I am free to 
withdraw at any time without giving a reason, without my medical care or legal 
rights being affected. 
 
 
     3. I understand that relevant sections of my medical notes and data 
collected during the study, may be looked at by individuals from the 
research team, from regulatory authorities or from the NHS Trust, where it is 
relevant to my taking part in this research. I give permission for these 
individuals to have access to my records.     
         
 
4. I agree to take part in the above study. 
  
 
 
___________________            _____________             _____________________ 
Name of Patient            Date      Signature 
 
 
___________________            _____________             _____________________ 
Name of Person            Date      Signature 
taking consent 
 
If you would like to be notified of the results of the study, please tick here         
 
When completed: 1 for patient; 1 for researcher site file; 1 (original) to be kept in medical 
